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Summary 
 
This project consisted of two distinct parts. First, a patient who suffered from and died 
of AML exhibited a rather unusual constellation of translocations. In a previous project 
the ETV6 locus, coding for a hematopoietic transcription factor, was shown to be 
affected by the translocation. The elucidation of the fusion partner of ETV6 and the 
characterization of the resulting fusion transcript were the goal of this project. 
With the help of RACE PCR, cloning, and sequencing the neurotrophic receptor kinase 
NTRK3 was identified as partner. FISH assays proved the existence of the underlying 
chromosomal translocation. Further molecular analyses unveiled the structural 
organization of the chimeric transcript. Additionally, alternative splicing of the NTRK3 
RNA was detected. The discovery of this exact fusion transcript turned out to be unique 
as it has not been previously described for AML.  
 
The second part of the project dealt with the identification of fusion genes again, though 
the intended method had to be established first.  
Two patients with eosinophilia constituted unusual translocations that have only been 
defined by conventional cytogenetic methods. The chromosomal breakpoints had to be 
specified with the help of bacterial artificial chromosomes (BACs).  
In a first and very time consuming step the obtainment of the import license for E.coli 
harboring BACs issued by the Ministry of Health, Family, and Youth was necessary to 
actually start working on this part of the project. The adequate BACs were searched for 
in different data bases and were then ordered over the internet at BACPAC Resources 
Center at Children’s Hospital Oakland Research Institute (CHORI) in California, USA. A 
suitable method for labeling BAC DNA had to be found in the next step. Finally, the most 
convenient way for hybridization of the self-labeled probes was developed so that this 
procedure could easily be adopted for routine cytogenetics if required. 
Fluorescently labeled BACs were then used to localize the breakpoints and to find genes 
affected by the translocation. In one case, a particular chromosomal region was tested 
for the existence of the breakpoint by covering up the area with different BAC probes. 
Unfortunately, no breakpoint could be located to the assumed chromosome band, 
indicating that conventional cytogenetics can be very tricky and sometimes additional 
analyses using appropriate probes may be required for exact evaluation of the 
translocation.  
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In the other case, self-labeled BAC probes were used to walk along a target 
chromosome arm until the breakpoint could be narrowed down to a smaller region. 
Additional BAC hybridization assays were used to identify the candidate gene, lipid 
phosphatase TPIP/TPTE2, which is most likely to be involved in the translocation.  
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Zusammenfassung 
 
Dieses Projekt setzte sich aus zwei Teilen zusammen. Ein Teil beschäftigte sich mit dem 
Fall eines AML Patienten, der eine recht ungewöhnliche Konstellation an Translokationen 
aufwies. In einem vorangegangen Projekt wurde bereits gezeigt, dass der ETV6 Locus, 
der für einen hämatopoetischen Transkriptionsfaktor kodiert, von einer Translokation 
betroffen ist. Das Ziel dieses Teilprojekts war es, den Fusionspartner von ETV6 zu 
ermitteln und das resultierende Fusionstranskript zu charakterisieren.  
Mit Hilfe von RACE PCR, Klonierungen und Sequenzanalysen wurde die neurotrophe 
Rezeptorkinase NTRK3 als Fusionspartner identifiziert. Fluoreszenz in-situ 
Hybridisierungen konnten schließlich die zugrunde liegende chromosomale Translokation 
beweisen. Durch weitere molekulare Analysen konnte zum einen der strukturelle Aufbau 
des chimären Transkripts beschrieben und zum anderen alternatives Spleißen der 
NTRK3-RNA festgestellt werden. Die Entdeckung genau dieses Fusionstranskripts stellte 
sich als einzigartig heraus, da es in dieser Form bei AML in der Literatur bisher noch 
nicht beschrieben wurde.  
 
Der zweite Teil des Projekts beschäftigte sich ebenfalls mit der Identifizierung von 
Fusionsgenen, jedoch musste die dafür vorgesehene Methode erst etabliert werden.  
Zwei Patienten mit Eosinophilie wiesen ungewöhnliche Translokationen auf, die 
routinemäßig nur mittels konventioneller Zytogenetik definiert wurden. Die 
chromosomalen Bruchpunkte sollten mit Hilfe von BACs weiter spezifiziert werden.  
Der erste und besonders zeitaufwändige Schritt bestand darin, die Einfuhrbewilligung 
von BACs zu erhalten, die durch das Bundesministerium für Gesundheit, Familie und 
Jugend ausgestellt wurde. Erst danach konnten die passenden BACs aus diversen 
öffentlich zugänglichen Internet-Datenbanken ausgesucht und über die Website von 
BACPAC Resources Center at Children’s Hospital Oakland Research Institute (CHORI) in 
Kalifornien bestellt werden. Weiters wurde eine adäquate Methode zur Herstellung von 
fluoreszenzmarkierten BAC-Sonden etabliert und die komfortabelste Arbeitsweise für 
Hybridisierungen gefunden, damit die Methode bei Bedarf einfacher für Routinearbeiten 
übernommen werden kann.  
Die fluoreszenzmarkierten BACs wurden schließlich verwendet, um Bruchpunkte zu 
lokalisieren und um Gene zu finden, die von der Translokation betroffen sind.  
In einem der beiden Patientenfälle wurde eine bestimmte chromosomale Region auf 
einen Bruchpunkt untersucht, indem dieser Bereich durch BAC-Sonden abgedeckt 
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wurde. Jedoch konnte kein Bruchpunkt in der angenommenen Chromsomenbande 
lokalisiert werden. Dieses Beispiel zeigte, dass konventionelle Zytogenetik sehr 
kompliziert sein kann und daher manchmal zusätzliche Analysen durch passende 
Sonden erforderlich sein können, um die Translokation genau zu definieren.    
Im weiteren Patientenfall wurden die BAC-Sonden verwendet, um entlang eines 
betroffenen Chromosomenarms zu wandern. Der Bruchpunkt wurde so auf einen 
weitaus kleineren Bereich eingeengt und weitere BAC-Hybridisierungen identifizierten 
ein Kandidat-Gen, Lipidphosphatase TPIP/TPTE2, das mit sehr hoher Wahrscheinlichkeit 
von der Translokation betroffen ist.  
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1  Introduction 
 
1.1  Hematopoiesis 
Hematopoiesis, from Ancient Greek haima meaning blood and poiesis meaning 
production [1], is the biological process by which the blood cells of an organism are 
formed. It is the mechanism that guarantees that the predominantly short lived blood 
cells are produced throughout life by means of hematopoietic stem cells (HSC) [2]. As 
with all stem cells, HSCs are capable of both self-renewal and differentiation [3]. 
Therefore, HSCs are able to produce additional HSCs (self-renewal) and give rise to all 
blood cell lineages (differentiation).   
HSCs normally reside in small numbers in the adult bone marrow where they are on top 
of a hierarchical tree of progenitor cells eventually differentiating into mature blood cells 
[2]. HSCs can be divided into three different populations depending on their maturation 
state: long-term self-renewing HSC (LT-HSC) giving rise to short-term self-renewing 
HSC (ST-HSC) which in turn give rise to multipotent progenitor (MPP) cells without self-
renewal potential. Multipotent progenitor cells differentiate either into common lymphoid 
progenitors (CLP) or common myeloid progenitors (CMP). CLPs generate the lymphoid 
lineages consisting of B and T lymphocytes, as well as natural killer (NK) cells and 
dendritic cells (DC). CMPs are the precursors of the myeloid lineage differentiating into 
erythrocytes, platelets, macrophages, granulocytes, and dendritic cells [3]. 
Granulocytes are further divided into three classes according to their morphology and 
staining properties: neutrophils, basophils, and eosinophils [4]. An overview of 
hematopoiesis is given in figure 1.1. 
1 Introduction 
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Hematopoiesis is a complex developmental process that involves various anatomical 
sites during embryogenesis including the yolk sac, the placenta and eventually the fetal 
liver. Postnatally, the bone marrow becomes the major site of hematopoiesis [6]. 
 
1.1.1 Regular and aberrant control of hematopoiesis 
Both survival promoting (anti-apoptotic) and death inducing (pro-apoptotic) molecules 
are involved in the process of survival, proliferation and differentiation of all progenitor 
and blood cell types [7] in order to maintain a finely tuned steady-state level of HSCs in 
the bone marrow which constantly provide progenitors for the various hematopoietic 
lineages. The differentiation of these lineages is a stepwise process characterized by the 
tightly regulated expression of transcription factors, growth factors such as cytokines, 
and growth factor receptors whose alternating combination determines a cell’s 
differentiation and maturation path [5]. The activity of these proteins must be very 
accurately regulated to maintain a homeostatic balance of these molecules. To date, 
more than two dozen ‘hematopoietic transcription factors’ exist of which nearly all were 
found to be associated with hematopoietic malignancies, i.e. leukemia. What makes the 
incidence of leukemia even more easily to occur is the fact that the transcription factors 
critical for hematopoiesis involve virtually all classes of DNA binding proteins, rather 
than just a particular family. The majority of the transcription factors contribute to 
Figure 1.1 Differentiation pathway of hematopoietic cells. MEP, megakaryocyte erythrocyte precursor; 
GMP, granulocyte macrophage precursor; NK, natural killer (picture from [5]). 
1 Introduction 
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hematopoietic malignancies as chimeric proteins produced by chromosomal 
translocations. Target genes are therefore inappropriately activated or repressed 
resulting in aberrant survival and apoptosis regulation [2,5]. Not only mutated 
transcriptional regulators contribute to the development of hematopoietic disorders but 
also other proteins including mutated growth factor receptors, kinases and intracellular 
signaling molecules such as the GTP binding Ras proteins. These mutations also allow 
affected cells to bypass normal control of growth, differentiation, and apoptosis [8].     
 
One particular transcription factor, ETV6, fundamental in adult hematopoiesis and its 
role in hematological malignancies are discussed in great detail below. Thereafter, two 
different forms of hematopoietic disorders will also be described as well: the pathogenic 
proliferation of myeloid progenitor cells resulting in AML, and the aberrant proliferation 
of eosinophilic cells resulting in eosinophilia.  
 
 
1.2  ETV6 – a versatile transcription factor 
The ETV6 (ets1 variant gene 6) or TEL2 gene on the short arm of chromosome 12 at 
band 12p13 encodes a transcriptional repressor of the ets transcription factor family 
[9]. It is a large family of transcriptional regulators with more than 45 members, which 
play important roles in a variety of cellular processes including proliferation, 
differentiation, migration/tissue remodeling, angiogenesis, apoptosis, as well as 
hematopoiesis and cell transformation [10,11]. Each ets family member possesses a 
highly conserved region of about 85 amino acids, the ets domain. It is a sequence 
specific DNA binding domain, which recognizes a purine rich GGAA/T motif in promoters 
and enhancers of various genes [9,10]. 
 
1.2.1 Structural organization and associated functional 
activities of the ETV6 protein 
ETV6 is a 452 amino acid protein encoded by 8 exons that bears its ets domain at its 
carboxy terminus [12,13]. The ets domain harbors DNA binding properties but also 
                                            
1 E26-transforming specific  
2  Transformation ets leukemia 
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mediates protein-protein interactions [9]. As with one third of ets family members, 
ETV6 contains a helix-loop-helix (HLH) domain (also known as pointed or SAM3 
domain), which mediates homotypic oligomerization of ETV6 molecules and also 
heterotypic interactions with other proteins of the transcriptional regulation apparatus 
or of signaling cascades [9,10]. See figure 1.2 for ETV6 structure. 
 
 
 
ETV6 activity as transcriptional repressor is achieved by at least two different domains: 
the HLH domain and the central region located between the SAM and ets domain [9,10] 
encoded by part of exon 4 and the entire exon 5. This central domain was shown to 
interact with corepressors like mSin3A/B or SMRT, which recruit histone deacetylases 
(HDAC), whereas the HLH domain represses gene transcription independently from 
corepressors [9,10,14]. Possibly, one of the two domains is preferentially active 
depending on the promoter or the physiologic state of the cell [14]. 
 
1.2.2 Expression profile and subcellular localization 
In contrast to most ets proteins, ETV6 is widely expressed in normal tissues [9,10] and 
it is relatively abundant in hematopoietic cells [15]. Two distinct isoforms of the ETV6 
protein exist that differ in their length by 42 amino acids due to an alternative start 
codon. Considering the major isoform that is pictured in figure 1.2 this alternative start 
codon lies within coding exon 2 and therefore both isoforms contain the HLH as well as 
the ets domain [12].  
ETV6 is predominantly found as a nuclear phosphoprotein. It was shown that a stretch 
of about 20 amino acids in the DNA binding domain is necessary for localization within 
the nucleus. However, the underlying mechanism is not understood [16]. 
                                            
3 Sterile alpha motif 
Figure 1.2 Schematic representation 
of ETV6. The structural organization of 
ETV6 with its exon and domain 
boundaries is demonstrated 
(illustrated according to [13]). 
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1.2.3 ETV6, its functions and its dysfunctions 
1.2.3.1 The physiological role of ETV6 
As mentioned earlier, ETV6 is a transcriptional repressor that works either by itself or in 
combination with other proteins called corepressors. Wang et al. showed that its 
functionality is essential in the mouse embryo where it is required for angiogenesis in 
the yolk sac and that embryos homozygous for ETV6 loss (ETV6-/-) die during embryonic 
development. Additionally, they showed that ETV6 was not necessary for fetal liver 
hematopoiesis, though it is the first transcription factor specifically required for bone 
marrow hematopoiesis in early postnatal life [15]. In the bone marrow ETV6 is needed 
for the production of erythroid, myeloid, mast, and megakaryocytic cells. As far as the 
committed lymphoid lineage is concerned, ETV6 is not required for the proliferation and 
differentiation per se but it is needed for maintenance of a normal pool of lymphoid 
progenitors in the bone marrow [15].   
Therefore, ETV6 plays an important role in the development and maintenance of HSCs 
and multipotent progenitors in the bone marrow niche. ETV6 is also said to probably be 
involved in adhesion-mediated cellular processes as ETV6-/- HSCs or progenitors fail in 
stably colonizing the bone marrow [15].  
Even though very little is known about the upstream regulators of ETV6 and its 
downstream targets, it is thought to function as a tumor suppressor. This idea is 
supported by its ability to inhibit growth of Ras transformed NIH3T3 fibroblasts and its 
ability to inhibit expression of a metalloproteinase that is elemental for tissue 
remodeling and tumor invasion [9,11]. Also, ETV6 is involved in a great number of 
translocations associated with leukemia. In such cases, one allele of the ETV6 locus is 
involved in a translocation while the other allele is often found to be deleted or 
inactivated. This, too, makes ETV6 a candidate tumor suppressor gene [10,17]. 
 
1.2.3.2 The leukemogenic role of ETV6 
All the above features of ETV6 were elucidated only after it was originally identified as 
the fusion partner of the platelet-derived growth factor receptor β (PDGFRB) which is a 
protein tyrosine kinase (PTK). The underlying translocation t(5;12)(q33;p13) and the 
expression of the resulting fusion gene, ETV6-PDGFRB, were critical for the development 
of chronic myelomonocytic leukemia (CMML) [9,12].  
ETV6 is located on band 12p13 which is genetically very unstable and fragile and thus 
susceptible to chromosomal rearrangements [17]. It is not very surprising that in the 
1 Introduction 
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last decade ETV6 was shown to be involved in a variety of translocations associated with 
hematological malignancies of both myeloid as well as lymphoid origin [9,18]. The 
diversity of ETV6 rearrangements is striking considering that the breakpoints do not 
cluster within a particular region of the gene [12]. For instance, in cases where ETV6 
constitutes the 5´ part of the fusion gene, transcripts can comprise the first 4 exons or 
alternatively exons 1 through 5 [19,20]. On the other hand when ETV6 constitutes the 
3´ part of the fusion, transcripts were shown to contain either exons 2 through 8 or 
exons 3 through 8 [21].  
As shown in figure 1.3, more than 20 fusion partners to the ETV6 gene locus are known 
to date and most of them are either tyrosine kinases or transcription factors [9,17]. 
 
 
 
 
 
 
 
The role of ETV6 in hematological malignancies resulting from translocations is not 
entirely understood. However, a few mechanisms by which ETV6 contributes to the 
aberrant function of fusion products have been proposed. For instance, if fused to PTKs, 
the HLH domain of ETV6 serves as dimerization module which allows homodimerization 
of the fusion product. Consequently, the kinase domain of the PTK becomes 
constitutively activated which in turn leads to autophosphorylation of the fusion protein 
and of downstream signaling molecules [9]. 
Fusions between ETV6 and PTKs are found in a variety of hematological diseases, e.g. 
CMML, AML, acute lymphoid leukemia (ALL) or myelodysplastic syndrome (MDS). They 
Figure 1.3 ETV6 and several of its fusion partners associated with leukemia. Generally, ETV6 constitutes 
the 5´part of the fusion genes unless otherwise indicated by a black arrow head. Red arrows indicate 
transcriptional upregulation whereas question marks denote that upregulation or its relevance requires 
additional data. Transcription factors highlighted in yellow belong to the Homeobox gene family (figure  
from [9]).  
 
1 Introduction 
- 16 - 
have also been described for solid tumors, like congenital fibrosarcoma or secretory 
breast carcinoma [9].   
 
The transcription factor RUNX1 (AML1) was the second fusion partner of ETV6 to be 
identified [9]. AML1, a transcriptional activator, plays an essential role in adult 
hematopoiesis, like ETV6 itself [9,15]. 
The ETV6-AML1 fusion turned out to be the most common fusion gene in pediatric B-cell 
ALL where it is detected in about 17% to 25% of all cases [9,18].  
It is not understood yet how this fusion disturbs the normal gene activation in 
hematopoiesis. However, data indicate that the chimeric protein still acts on AML1 
target genes but it represses rather than activates transcription of target genes. Both 
the ETV6 HLH domain as well as the central domain is necessary for repression of AML1 
targets [9].  
In cases of aberrant MN1-ETV6, PAX5-ETV6 or HLXB9-ETV6 fusions, the ets domain of 
ETV6 seems to contribute to dysregulation via its DNA binding domain [9,22]. 
 
As can be seen from the above information on ETV6 and its fusion partners a lot of work 
remains to be done in order to elucidate the molecular mechanisms driving the 
oncological path of hematopoiesis.  
 
 
1.3  Acute myeloid leukemia (AML) 
AML is a clonal disease of myeloid precursors showing defective maturation and genetic 
abnormalities [23,24]. The failure in differentiation of myeloid stem cells results in the 
accumulation of wildly proliferating, non-functioning, immature cells called blasts 
[25,26]. In healthy persons, circulating blast cells are very rare and constitute about 
0,1% of mononuclear cells [24]. 
Blast cells are easily distinguished form normal hematopoietic cells in blood or bone 
marrow samples because of their characteristic appearance. They measure 12 to 20 µm 
in diameter and have a high nucleocytoplasmic ratio with a round or slightly oval 
nucleus [24]. The cytoplasm is basophilic and appears pale blue [23,24]. The nucleus 
shows a fine, dense chromatin structure with several nucleoli [23]. Figure 1.4 brings out 
the difference between healthy bone marrow cells and malignant accumulation of blasts. 
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1.3.1 Epidemiology and etiology 
AML accounts for approximately 25% of all adult leukemia in the Western World and is 
therefore the most common type of leukemia in adults. Nevertheless, it has the lowest 
survival rate of all hematological malignancies. AML is a consistently fatal disease with a 
mortality rate higher for males than for females. The U.S. age-adjusted mortality rate is 
at 3,5 and 2,2 per 100.000 for males and females, respectively. [27].  
In 2004, an Italian study with 1005 participating AML patients showed that median 
survival of patients age >60 years was only 5 to 7 months despite therapy.  
Many risk factors contribute to the development of AML, including age, precedent 
hematological disease and genetic disorders, as well as exposure to radiation or 
chemotherapy. The latter being able to induce AML (secondary AML) in 10% to 20% of 
patients who were treated for other malignancies between 5 or 10 years earlier [27]. 
  
1.3.2 Classification of AML disease 
Different manifestations of AML are categorized according to peripheral blood and bone 
marrow features. To date, the French-American-British (FAB) classification of AML is 
most generally accepted, albeit the World Health Organization (WHO) classification will 
be increasingly adopted. There is one very important difference between these two 
classifications. According to the FAB classification the bone marrow blast cell percentage 
must be at least 30%, whereas AML is diagnosed with 20% bone marrow blast cells 
according to the WHO classification [24]. 
 
Figure 1.4 A, B Healthy versus malignant bone marrow cells. Normal bone marrow smear is shown in A, 
whereas B demonstrates bone marrow cells from a patient suffering from the AML subtype M0 (pictures 
from [23]). 
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Table 1.1 FAB classification of AML [23,24] 
M0 
AML with minimal myeloid 
differentiation 
blasts of myeloid origin, <3% of blasts 
MPO negative 
M1 AML without maturation 
>90% blasts, >3% of blasts MPO 
positive, <10% mo, <10% gra 
M2 AML with granulocytic maturation 30-89% blasts, >10% gra, <20% mo 
M3 acute promyelocytic leukemia hypergranular, Auer rods, <20% mo 
M3v hypogranular variant of M3 
hypogranular, monocytoid nuclei, <20% 
mo 
M4 acute myelomonocytic leukemia >30% blasts, >20% gra, >20%mo 
M4Eo 
acute myelomonocytic leukemia with 
eosinophilia 
>30% blasts, >20% gra, >20%mo, 
abnormal eosinophil count 
M5a acute monoblastic leukemia >80% mo immature 
M5b acute monocytic leukemia >80% mo mature 
M6 erythroleukemia >30% blasts, >50% ery 
M7 acute megakaryoblastic leukemia 
>30% blasts (megakaryoblasts, 
CD41/CD61 positive) 
MPO, myeloperoxidase; gra, granulocytopoiesis; mo, monocytopoiesis; ery, erythropoiesis. 
 
The WHO classification is somewhat differently organized and considers cytogenetic 
aberrations and gene rearrangements, most of which are chromosomal translocations 
resulting in fusion genes. 
Table 1.2 shows the WHO classification of AML which was adopted from reference [23]. 
The latest version of the WHO classification of hematopoietic malignancies (WHO 
Classification of Tumours of Haematopoietic and Lymphoid Tissues, New Fourth Edition) 
was released in 2008. 
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Table 1.2 Classification of AML according to the WHO (adopted from reference [23]) 
AML with recurrent cytogenetic abnormalities 
- AML with t(8;21)(q22;q22): AML1-ETO 
- AML with abnormal BM eosinophils inv(16)(p13q22): CBFβ-MYH11 
- acute promyelocytic leukemia with t(15;17)(q22;q12): PML-RARα 
- AML with 11q23 (MLL) abnormalities 
AML with multilineage dysplasia 
AML and myelodysplastic syndromes, therapy-related 
AML not otherwise categorized 
- AML minimally differentiated 
- AML without maturation 
- AML with maturation 
- acute myelomonocytic leukemia 
- acute monoblastic and monocytic leukemia 
- acute erythroid leukemia 
- acute megakaryoblastic leukemia 
- acute basophilic leukemia 
- acute panmyelosis with myelofibrosis 
- myeloid sarcoma 
Acute leukemia of ambiguous lineage 
- undifferentiated acute leukemia 
- bilineal acute leukemia 
- biphenotypic acute leukemia 
BM, bone marrow. 
 
1.3.3 Chromosomal aberrations as prognostic factors 
Considering the above information it becomes clear that AML is a very heterogeneous 
disease with regard to clinical features and genetic defects. Acquired genetic defects do 
not only provide a basis for development of AML, they are also very important 
prognostic factors for therapy outcome [8]. 
 
All large cytogenetic studies of AML cases showed that patients harboring 
t(15;17)(q22;q12-21) have an excellent prognosis and those with t(8;21)(q22;q22) or 
inv(16)(p13q22) have a relatively favorable prognosis. Patients exhibiting monosomies 
of chromosomes 5 and 7 or deletions in the long arms of these and patients with a 
complex karyotype, i.e. controversially defined as at least 3 or at least 5 chromosomal 
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aberrations, have a poor clinical outcome [28,29]. The MLL gene located at 11q23 
occasionally undergoes partial tandem duplication which was demonstrated, too, to be 
an unfavorable prognostic factor [30]. 
About 45-60% of patients with AML showing a normal karyotype carry a mutation in the 
NPM1 (nucleophosmin 1) gene. This mutation is said to confer good prognosis, however, 
will be overridden by FLT3 mutations (internal tandem repeats) if existent alongside 
NPM1 mutations [31]. 
Nevertheless, the age of the patient remains the most important prognostic factor, as 
the outcome definitely deteriorates with increasing age [29]. 
 
 
1.4  Eosinophilia 
Eosinophilic cells derive from myeloid progenitors and represent a subgroup of 
granulocytes. They play an important role in immune responses as they destroy 
parasites and they also contribute to the pathological mechanisms of allergic reactions 
[32]. Eosinophil development is considerably influenced by cytokines such as GM-CSF4, 
and interleukins IL-3 and IL-5, with only the latter displaying specificity for eosinophils. 
The major source of the eosinophil specific IL-5 is a subset of T lymphocytes called type 
2 helper T cells (TH2) [33].  
In healthy adults, circulating eosinophils constitute about 1% to 5% of the total white 
blood cell count (i.e. 50-400 µl-1) [32]. If the count of eosinophils is elevated above the 
indicated number, a condition called eosinophilia arises [24].  
 
1.4.1 Classification of eosinophilia and its causes 
Depending on the degree of eosinophilic increase one distinguishes between mild 
(<1500 µl-1), moderate (1500-5000 µl-1) and severe (>5000 µl-1) subtypes [34]. 
Furthermore, depending on its causes, eosinophilia is divided into three categories [35]: 
1. reactive (non-clonal) eosinophilia 
2. clonal disorder originating in the bone marrow associated with eosinophilia 
3. hypereosinophilic syndrome (HES) 
 
                                            
4 Granulocyte-macrophage colony stimulating factor 
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Reactive eosinophilia results from cytokines that stimulate eosinophilic proliferation. 
Such cytokines, e.g. IL-5, are produced mainly by TH2 cells, yet also eosinophils 
themselves secrete these molecules allowing autocrine fashion of their proliferation. 
Eosinophilia due to cytokines produced by T cells can be associated with all kinds of 
illnesses like for instance infections, allergies, skin or connective tissue diseases, cardiac 
or pulmonary diseases or malignancies [34,35]. 
In clonal eosinophilia a specific genetic abnormality leads to hematopoietic progenitor 
cell disorders in the bone marrow, e.g. chronic eosinophilic leukemia (CEL) with FIP1L1-
PDGFRα fusion gene [36]. 
The hypereosinophilic syndrome (HES) is diagnosed when (a) elevated eosinophil levels 
(>1500 µl-1) are persistent for at least six months, (b) evidence for end organ damage 
due to hypereosinophilia is provided, and (c) other causes of eosinophilia such as 
infectious, allergic or malignant disorders can be excluded. Some cases of HES have 
also been shown to involve the FIP1L1-PDGFRα fusion gene [33].  
 
1.4.2 FIP1L1-PDGFRα fusion in eosinophilia 
The fusion of the FIP1L1 gene to the PDGFRα gene is quite unusual as it does not 
happen by a chromosomal translocation but rather via a cryptic deletion of ~ 800 kb 
[36]. This deletion on chromosome 4q12 is not visible by routine karyotyping but can be 
detected by FISH techniques or reverse transcriptase PCR (RT-PCR) analysis [33,36].  
The fusion involves highly variable breakpoints in FIP1L1 (scattered over introns 7-10) 
and less variable breakpoints in PDGFRα (restricted to exon 12) and produces the 
constitutively active tyrosine kinase FIP1L1-PDGFRα. The molecular mechanisms of the 
chimeric kinase leading to eosinophilic differentiation are not understood yet [35].  
Interestingly, imatinib, approved treatment for BCR-ABL positive CML patients, also 
shows great success in medical therapy of FIP1L1-PDGFRα positive eosinophilias [36]. 
 
1.4.3 Clinical manifestations   
Complications due to pathologically acting eosinophils involve the release of granule 
molecules such as eosinophil cationic protein (ECP), major basic protein (MBP), 
eosinophil derived neurotoxin (EDN), or enzymes like eosinophil peroxidase (EPO), 
elastase and collagenase [33]. Together with infiltration of tissues these granule 
contents provoke thrombosis, endothelial damage or neurotoxic implications. The 
organs most commonly damaged by eosinophil proteins are skin (predominant 
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complication), heart (congestive heart failure), nervous system (from memory loss to 
stroke) and lungs [33,34].  
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2  Aim of the project 
 
2.1  Routine diagnostics 
In routine laboratory diagnostics hematological disorders are adjudged due to 
specifically developed molecular biological and cytogenetic tests.  
Material of patients with clinical suspicion of distinct hematological diseases is sent from 
various Austrian hospitals, from which nucleic acids of peripheral blood and bone 
marrow cells are prepared for molecular biological analysis. For cytogenetic studies 
mainly bone marrow cultures are established from which a karyogram is made for each 
patient which gives first hints for whether or not some chromosomal aberrations are 
existent. In combination with the results of the requested molecular biological tests 
suspicion of disease can be either confirmed or eliminated. It can also lead to further 
investigation, especially on the level of cytogenetics, in particular FISH studies. 
Going through the whole process of analysis one is often confronted with unusual 
genotypes in hematological diseases. These are for example cases of leukemia with 
atypical translocations that have not been described yet, or translocations probably 
linked to some interesting forms of pathological phenotypes, i.e. strong increase in the 
number of eosinophilic cells.  
Such diagnostic findings are not further assayed in routine work, instead these cases 
are subject to further investigation in separate projects.  
 
 
2.2  Where routine ends and special tasks begin  
The elucidation of such unusual cases was the aim of this project.  
Generally, the identification of fusion genes and their resulting chimeric transcripts and 
proteins is of great importance in cancer, especially leukemia, therapy. Effective medical 
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therapeutic drugs can only be developed if the underlying mechanisms of disease origin 
are known. The elucidation of diverse genetic rearrangements is the first step in this 
very time-consuming and laborious process. If a patient’s genetic make up is known, 
physicians can more easily apply targeted therapy.  
Therefore, the identification of novel gene fusions is a very valuable aspect in clinical 
matter. Genetic analysis of the tumor represents the basis for future possibilities in 
patient specific therapy with minimal side effects.  
 
In the first part of this project, the case of an AML patient attracted a great deal of 
attention when an unusual constellation of chromosomal aberrations was detected. As a 
consequence of translocations, distinct fusion genes are very likely to arise. Considering 
the existent translocation on chromosome 12p13 and comparing this case with 
publications concerning fusion genes in leukemia, ETV6 on chromosome 12 emerged as 
possible candidate gene in this rearrangement. Indeed, the transcription factor ETV6 
was shown to constitute one part of the resulting fusion gene. The partner gene was to 
be identified and characterized with the help of both elegant and standard methods. 
 
Secondly, the work with BACs had to be established in the laboratory.  
After successful introduction of BAC methods, these, too, should be used to identify 
putative fusion genes that resulted from a translocation. For these cases, both of which 
were associated with eosinophilia, data from conventional cytogenetics, i.e. karyograms, 
were available only. Thus, the area of the breakpoint had to be narrowed down. BAC-
FISH was the tool of choice to walk along chromosomes to define the breakpoint and 
identify genes involved in the rearrangement.  
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3  Materials and Methods 
 
3.1  Patient histories and profiles 
 
Patient A – male, born in 1951 
In 2005 patient A was diagnosed with undifferentiated AML (M0 according to the FAB 
classification) due to diverse molecular biological tests, cytogenetic studies, FACS 
analysis, and histological examination.   
The translocation t(8;21) giving rise to the AML1-ETO fusion gene often seen in AML 
was not detected, neither was the inversion of chromosome 16 which results in another 
fusion gene, CBFβ-MYH11, typical for AML.   
Karyograms of unstimulated bone marrow cultures and FISH studies showed the 
existence of a mosaic. Two pathological cell lines were discovered, one of them 
exhibiting monosomy 7 and the translocation t(10;12) and the second one exhibiting 
monosomy 7, t(10;12) and an additional translocation between chromosome 12 and an 
acrocentric chromosome. The involved band on chromosome 12 was assumed as 12p13. 
In a previous project the transcription factor ETV6 on chromosome 12p13 was shown to 
constitute the 5´ part of the fusion gene. 
Despite chemotherapy the patient died due to progression of disease 9 months after 
diagnosis.  
 
Patient B – male, born in 1931  
Due to cytological examinations in early 2008 patient B was found to show considerable 
increase in eosinophilic cells which constituted 60% of total bone marrow cell count. 
Thus, indication of hypereosinophilic syndrome arose. Additionally, a relative increase in 
so-called T-NK cells was present in both peripheral blood and bone marrow samples. 
The translocation t(8;21)(q22;q22), one of the most frequent chromosomal 
abnormalities associated with AML [5], was not existent according to both molecular 
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biological tests and FISH studies. Moreover, the fusion gene FIP1L1-PDGFRA was 
detected neither in peripheral blood nor in bone marrow samples. Additionally, abnormal 
T cell proliferation could be ruled out due to negative results for TCR γ rearrangement 
PCR.  
As far as cytogenetic studies are concerned, a chromosomal mosaic was found. Next to 
a cell line with loss of chromosome Y, which is probably attributed to advanced age, 
another cell line with a translocation between chromosomes 9 and 21 in addition to loss 
of chromosome Y was detected. The translocation was subsequently shown to be non-
constitutional. Hence it was thought to be associated with the strongly increased 
number of eosinophils.  
 
Patient C – male, born in 1925  
In early 2008 immunological phenotyping of patient C bone marrow detected a 
prominent increase in eosinophilic cells to 50%. Additionally, a pathological B cell 
population was detected. Due to the existing eosinophilia, suspicion of hypereosinophilic 
syndrome, Churg Strauss syndrome5 or eosinophilic leukemia emerged.  
The fusion gene FIP1L1-PDGFRA could not be detected in peripheral blood or in bone 
marrow samples. The existence of a clonal B cell population was proven by PCR analysis 
of Ig heavy chain rearrangements.  
Cytogenetic studies revealed a translocation t(4;13)(q35;q12) as mosaic with loss of 
chromosome Y, the latter event being probably attributed to advanced age. The 
translocation was thought to be associated with the increase in eosinophilic cells and 
was therefore subject to further investigation to identify genes possibly playing a role in 
the pathological process.  
 
3.1.1 Patient material 
For the diploma thesis at hand previously prepared material of the above patients was 
used. On the one hand extracted nucleic acids and on the other hand bone marrow cells 
in Carnoy’s fixative (3:1 methanol to glacial acetic acid) were available.  
                                            
5 A type of vasculitis characterized by pulmonary infiltrates. 
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3.2  Molecular Biological Methods 
Unless otherwise indicated, Aqua Bidest. “Fresenius” (Fresenius Kabi) or alternatively 
Ecotainer® Aqua B. Braun (B. Braun) was used for all reactions and is designated as 
ddH2O only.  
 
3.2.1 Bacterial strain 
For cloning experiments the chemically competent TOP10 E.coli strain (Invitrogen) was 
used. 
 
3.2.2 Media and culture plates  
For production of selective liquid media and selective culture plates kanamycin sulfate 
(Kan; SIGMA®) or chloramphenicol (CAM; SIGMA®) was added in a working 
concentration of 50 µg/ml or 12,5 µg/ml, resp. Both stock solutions, the 10 mg/ml 
kanamycin (in ddH2O) and the 25 mg/ml chloramphenicol (in EtOH absolute, Merck), 
were sterile filtered using a 0,2 µm filter (Sarstedt). 
 
LB liquid medium  10 g LB Broth Base (SIGMA®) 
    500 ml ddH2O 
    autoclave for 15 minutes at 121°C  
store at 4°C 
 
LB agar   16 g LB Agar (SIGMA®) 
    500 ml ddH2O 
    autoclave for 15 minutes at 121°C  
store at 4°C 
 
3.2.3 cDNA synthesis 
For cDNA synthesis 2 µg RNA were diluted in DEPC treated ddH2O to a final volume of 
11 µl. After adding 1 µl 250 ng/µl Random Primer (Amersham Biosciences) the reaction 
was incubated at 65°C for 5 minutes, chilled on ice for another 5 minutes and briefly 
centrifuged. Now 1 µl 10 mM dNTP mix (Amersham Biosciences), 6 µl M-MLV RT 5x 
Buffer (Promega), 0,5 µl Rnasin® Plus (40 U/µl; Promega) and 1 µl M-MLV RT, Rnase 
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(H-) Point Mutant (200 U/µl; Promega) were added, mixed and incubated at 42°C for 
one hour. The reaction was stopped by incubation at 70°C for 15 minutes, then it was 
cooled on ice, briefly centrifuged, mixed and could be stored at -20°C until further use.  
 
DEPC treated ddH2O 0,1% DEPC (SIGMA
®) in ddH2O  
shake well and incubate over night at 37°C  
autoclave and store at room temperature 
 
3.2.4 Polymerase chain reaction (PCR) 
The following PCRs were run either in the Mastercycler ep gradientS (Eppendorf) or 
alternatively in the PCR Express thermal cycler (Hybaid). The primers used for PCR (and 
sequencing, see 3.2.13) were designed with the help of Gene Runner Version 3.05 
(Copyright © 1994 Hastings Software, Inc.) and the online available software Primer3 
[37] and the Oligo Java-Applet on the TIB-MolBiol Homepage (OLIGO-Applet © 1998 by 
O.Landt/M.Peters-TIB Molbiol Berlin). The primers were ordered at and synthesized by 
Applied Biosystems, Metabion, TIB Molbiol or genXpress. For primer sequences refer to 
Appendix. 
 
3.2.4.1  Amplification of unknown cDNA ends 
In order to amplify cDNA strands with unknown 3´ ends a technique called 3´RACE PCR 
was performed using the GeneRacerTM Kit (Invitrogen, Austria).  
 
The mRNA’s PolyA tail is exploited when Oligo dT primers are annealed to the cDNA and 
reverse transcription is performed. As the Oligo dT primer has a defined 36 nucleotide 
sequence attached to it, regular PCR can be performed with the gene specific forward 
primer and a reverse primer complementary to the attached sequence of the Oligo dT 
primer. For increased specificity nested PCR was run subsequently. 
 
For cDNA synthesis 1 µg of total RNA was used. 1 µl GeneRacerTM Oligo dT Primer (50 
µM), 1 µl dNTP mix (10 mM each), and DEPC treated water ad 13 µl were added.  
The mixture was incubated at 65°C for 5 minutes, chilled on ice for > 1 minute and 
centrifuged briefly.  
Four µl 5x First Strand Buffer, 1 µl 0,1 M DTT, 1 µl RnaseOut (40 U/µl) and 1 µl 
SuperScript III RT (200 U/µl) were added to reach a final volume of 20 µl. After 
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incubation at 50°C for 45 minutes, the reaction was stopped by incubation at 70°C for 
15 minutes. The mix was chilled on ice, centrifuged briefly at maximum speed and 1 µl 
RnaseH (2 U) was added. RNA digestion occurred for 20 minutes at 37°C. Now cDNA 
was ready for RACE PCR.   
 
Three separate reactions were run in order to cover up a wider part of the ETV6 
transcript sequence. Therefore, RACE PCR was performed using the GeneRacer primer 
and one of three different gene specific primers (ETV6A, ETV6B, ETV6C) each. The 
primers were designed with regard to the major isoform of ETV6 (for transcript 
sequence information refer to Appendix). 
For the reaction 1 µl cDNA, 3 µl 10 µM GeneRacerTM 3´ primer, 1 µl 10 µM ETV6 primer, 
5 µl 10x High Fidelity PCR Buffer (Invitrogen), 1 µl 10 mM dNTP mix, 0,5 µl Platinum® 
Taq DNA Polymerase High Fidelity (5 U/µl; Invitrogen), 2 µl 50 mM MgSO4 and ddH2O 
were added to a final volume of 50 µl. 
 
 
Table 3.1 Hot start and touchdown PCR program used for RACE PCR 
Step Time, Temperature Cycles 
Initial denaturation 2 min at 94°C 1 
Denaturation 30 sec at 94°C 
5 
Annealing, extension 2 min at 72°C 
Denaturation 30 sec at 94°C 
5 
Annealing, extension 2 min at 70°C 
Denaturation 30 sec at 94°C 
25 Annealing 30 sec at 65°C 
Extension 2 min at 68°C 
Final extension 10 min at 68°C 1 
 
For nested PCR 1 µl of 1:100 diluted initial PCR product, 1 µl 10 µM GeneRacerTM 3´ 
nested primer, 1 µl 10 µM ETV6 nested primer (ETV6Anested, EVT6Bnested or 
ETV6Cnested), 5 µl 10x High Fidelity PCR Buffer (Invitrogen), 1 µl 10 mM dNTP mix, 0,5 
µl Platinum® Taq DNA Polymerase High Fidelity (Invitrogen; 5 U/µl), 2 µl 50 mM MgSO4 
and ddH2O were mixed in a final volume of 50 µl. 
 
Table 3.2 PCR program used for nested RACE PCR  
Step Time, Temperature Cycles 
Initial denaturation 2 min at 94°C 1 
Denaturation 30 sec at 94°C 
25 Annealing 30 sec at 65°C 
Extension 2 min at 68°C 
Final extension 10 min at 68°C 1 
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3.2.4.2  PCR on a plasmid DNA template  
The RACE PCR products were cloned into the pCR®4-TOPO® vector (Invitrogen) from 
which the fragments between the M13 Reverse and M13 Forward (-20) priming sites 
could be amplified for subsequent sequencing.  
 
0,5  – 1 ng plasmid DNA, 5 µl 10x PCR Gold Buffer (Applied Biosystems), 5 µl 25 mM 
MgCl2 (Applied Biosystems), 1 µl 10 mM dNTP mix (Amersham Biosciences), 1 µl 10 
pmol/µl M13F primer (Applied Biosystems), 1 µl 10 pmol/µl M13R primer (Applied 
Biosystems), 0,4 µl AmpliTaq GoldTM DNA Polymerase (5 U/µl; Applied Biosystems) and 
ddH2O were mixed in a final volume of 50 µl. 
 
Table 3.3 PCR program used for amplification from a plasmid template 
Step Time, Temperature Cycles 
Initial denaturation 2 min at 94°C 1 
Denaturation 
Annealing 
Extension 
1 min at 94°C 
30 sec at 55°C 
2 min at 72°C 
25 
Final extension 10 min at 72°C 1 
Pause ∞ at 12°C - 
 
3.2.4.3  Reverse transcriptase PCR (RT-PCR)  
For RT-PCR experiments cDNA was used non-diluted and was mixed with 5 µl 10x PCR 
Gold Buffer (Applied Biosystems), 5 µl 25 mM MgCl2 (Applied Biosystems), 1 µl 10 mM 
dNTP mix (Amersham Biosciences), 1 µl 10 pmol/µl forward primer, 1 µl 10 pmol/µl 
reverse primer, 0,4 µl AmpliTaq GoldTM DNA Polymerase (5 U/µl; Applied Biosystems) 
and ddH2O to reach a final volume of 50 µl. 
 
Table 3.4 PCR program used for reverse transcriptase PCR experiments 
Step Time, Temperature Cycles 
Initial denaturation 2 min at 94°C 1 
Denaturation 
Annealing 
Extension 
30 sec at 94°C 
30 sec at 55°C 
1 min at 72°C 
35 
Final extension 10 min at 72°C 1 
Pause ∞ at 12°C - 
 
All PCR products were analyzed by agarose gel electrophoresis.  
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3.2.5 Agarose gel electrophoresis 
Agarose gel electrophoresis served a double purpose. Firstly, to separate fragments 
according to size, and secondly, to estimate the DNA amount in the PCR reaction for 
subsequent sequencing analysis.      
Depending on the size of the PCR products 1% or 2% agarose gels were made. Agarose 
MP (Roche) was dissolved in 0,5x TBE (SIGMA®) by heating in the microwave. After 
cooling, ethidium bromide (10 mg/ml, Amresco) was added in a working concentration 
of 0,5 µg/ml. 
 
The samples were mixed with 6x Loading Dye and loaded on the gel. Depending on the 
expected band sizes, the O´RangeRulerTM 200 bp DNA Ladder (Fermentas), pUC19 Hpa 
II DNA Marker (Fermentas) or the MassRulerTM DNA Ladder, Low Range (Fermentas) 
was used as marker and the gel was run in 0,5x TBE at 110 – 140 V depending on the 
size of the gel chamber. For illustration of the markers refer to Appendix.  
 
3.2.6 Gel extraction 
The bands of interest of the nested RACE PCR were excised from the agarose gel with a 
fresh razor blade for each band. The gel piece was transferred onto the S.N.A.P. 
columns included in the GeneRacerTM Kit. Depending on the size of the gel piece, 20 - 
60 µl DNA were collected in a microcentrifuge tube by centrifugation for 1 minute at 
13.000 rpm (Heraeus Biofuge Pico) and could now be stored at -20°C until further use.  
 
3.2.7 TOPO TA cloning 
Gel extracted nested RACE PCR products were cloned into the pCR®4-TOPO® vector 
using the TOPO TA Cloning® Kit for Sequencing (Invitrogen).  
 
The pCR®4-TOPO® vector used for cloning is linearized with single 3´ thymidine (T) 
overhangs and a topoisomerase covalently bound to it (also referred to as “activated” 
vector). Taq polymerase used in previous PCR amplifications has a nontemplate-
dependent terminal transferase activity which adds a single deoxyadenosine (A) to the 
3´ ends of PCR products. This allows PCR products to ligate with the vector via A-T base 
pairing.  
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Viral topoisomerase I binds specifically to duplex DNA and cleaves one strand after 5´-
CCCTT. The energy from the broken phosphodiester backbone is conserved by a 
covalent bond between the 3´ phosphate of the cleaved DNA strand and a tyrosyl 
residue (Tyr-274) of the enzyme. The phospho-tyrosyl bond can subsequently be 
attacked by the 5´ hydroxyl group of the original cleaved strand which reverses the 
reaction and releases the topoisomerase enzyme. TOPO® Cloning exploits this reaction 
to efficiently ligate PCR products with the vector [38], see figure 3.1. 
 
 
 
 
The use of the pCR®4-TOPO® vector allows direct selection of recombinants as it 
contains the lethal E.coli gene ccdB fused to the C-terminus of the LacZα fragment. If a 
PCR product is successfully cloned into the vector the expression of the LacZα−ccdB 
gene fusion is disrupted thus permitting growth of only recombinants upon 
transformation of TOP10 cells [38]. For pCR®4-TOPO® vector map refer to Appendix.  
 
The cloning reaction consisting of 4 µl PCR product, 1 µl Salt Solution and 1 µl TOPO® 
vector was mixed gently and incubated at room temperature for 30 minutes. The 
reaction was kept on ice until proceeding with the transformation.  
 
3.2.8 Transformation of One Shot® TOP10 chemically 
competent E.coli 
Transformation of competent cells was performed with reagents included in the TOPO 
TA Cloning® Kit for Sequencing (Invitrogen). 
 
After thawing the competent cells (50 µl) on ice, 2 µl of the cloning reaction were 
added, gently mixed and incubated on ice for 5-30 minutes. After a heat shock at 42°C 
Figure 3.1 Activated vector in ligation process. Interaction 
between vector DNA, PCR product and Topoisomerase I during 
cloning process is demonstrated (figure from [38]).  
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for 30 seconds the cells were immediately put on ice. The transformed cells were mixed 
with 250 µl room temperature S.O.C. medium and shaken for one hour at 37°C. 
The cells were cultivated on pre-warmed LB/Kan plates over night at 37°C in an 
incubator with natural convection, type BD53 (Binder). 
 
3.2.9 Plasmid DNA isolation 
All incubation steps of cells in liquid medium were done in a water bath type 1092 (GFL) 
whereas culture plates were incubated in an incubator with natural convection, type 
BD53 (Binder). 
 
3.2.9.1  Plasmid mini preparation using the TENS method 
All centrifugation steps in this procedure were done at 4°C in the Centrifuge 5415R 
equipped with the rotor F-45-24-11 (Eppendorf). 
A single colony was picked with a sterile toothpick and 5 ml LB/Kan medium were 
inoculated. The cells were grown over night at 37°C with vigorous shaking (~ 220 rpm).  
Cells were harvested by centrifugation of 1,5 ml of the overnight culture at 13.200 rpm 
for 30 seconds. The supernatant was discarded and the pellet was resuspended in the 
residual medium. Three-hundred µl TENS were added and mixed thoroughly. In the next 
step 150 µl 3 M NaOAc pH 5,2 were added, mixed and centrifuged for 5 minutes at 
13.200 rpm. The supernatant was now transferred to a new tube and 900 µl ice cold 
EtOH absolute (Merck) were added and mixed. The DNA was pelleted by centrifugation 
at maximum speed for 30 minutes and washed twice with 1 ml 70% EtOH each. 
EtOH was discarded and the pellet was dried at ambient temperature under vacuum in 
the UNIVAPO 100 H (UniEquip) for about 20 minutes. Finally, the dry pellet was 
dissolved in 100 µl TE buffer.  
 
3 M NaOAc   20,4 g NaOAc . 3 H2O (Merck) 
add 20 ml ddH2O  
adjust pH to 5,2 using glacial acetic acid (Merck) 
ad 50 ml with ddH2O 
 
TENS   0,1 N NaOH (Merck) 
   0,5 % SDS (SIGMA®) 
   ad 50 ml with TE pH 8,0 (MP Biomedicals) 
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3.2.9.2  BAC DNA isolation 
Generally, BACs are plasmids that contain a chromosomal DNA insert of up to 150 kb or 
even more. For our purposes BACs containing specific human genomic sequences were 
used.  
BACs were ordered at the BACPAC Resources Center at Children’s Hospital Oakland 
Research Institute (CHORI) in California, USA. They arrived as LB stabs containing 12,5 
µg/ml chloramphenicol. The DH10 E.coli host harbors the genomic fragment of interest 
cloned into either the pBACe3.6 or pTARBAC2 vector. For vector maps and a complete 
table of BACs used refer to Appendix. 
 
BAC DNA was isolated using the QIAGEN® Plasmid Midi Kit (QIAGEN) in combination 
with the User-developed Protocol.  
 
All centrifugation steps in this procedure were performed at 4°C in the centrifuge 
ROTANTA/TR (Hettich).  
 
A sterile toothpick was used to inoculate 5 ml LB/CAM medium with cells from the LB 
stab. The cells were grown over night at 37°C and 220 rpm. The next day the over night 
culture was streaked out on LB/CAM plates and incubated over night at 37°C.  
The next morning a single colony was picked and 5 ml LB/CAM were inoculated to grow 
a starter culture at 37°C and 220 rpm. Five-hundred µl of the starter culture were used 
in the evening to grow an over night culture in 100 LB/CAM at 37°C and 230 rpm. 
The next day, the cells were divided into two 50 ml tubes and harvested by 
centrifugation at 4500 rpm for 20 minutes. 
Each cell pellet was resuspended completely in 10 ml Buffer P1 (containing RnaseA in a 
concentration of 100µg/ml) by pipetting up and down and by harsh vortexing.   
For cell lysis 10 ml Buffer P2 were added to each tube, mixed thoroughly but gently by 
inverting 4-6 times and incubated at room temperature 5 minutes.  
Then 10 ml chilled Buffer P3 were added to each tube, immediately mixed by gently 
inverting 4-6 times, and incubated on ice for 15 minutes.  
Centrifugation at 4500 rpm for 30 minutes pelleted the cell debris and the supernatant 
containing the plasmid was removed as quickly as possible. The supernatant was 
centrifuged again at 4500 rpm for 15 minutes and the supernatants of both tubes were 
removed and pooled. Meanwhile, one QIAGEN-tip 100 for each over night culture was 
equilibrated by applying 4 ml Buffer QBT and the column was allowed to empty by 
gravity flow.  
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After equilibration the supernatant was applied to the QIAGEN-tip 100 and was allowed 
to enter the resin by gravity flow. 
Subsequently, the column was washed twice with 10 ml Buffer QC each and DNA was 
eluted with 5x 1 ml of prewarmed (65°C) Buffer QF. 
DNA was precipitated by adding 3,5 ml room temperature isopropanol, mixing by 
inverting and centrifugation at 4500 rpm for 1 hour. The pellet was washed with 2 ml of 
room temperature 70% EtOH and centrifuged at 4500 rpm for 30 minutes. 
Finally, the pellet and was air-dried for 5-10 minutes and dissolved in a suitable volume 
(30 – 70 µl) of TE buffer. 
 
Plasmid DNA concentration of both mini preparations and BAC DNA isolations was 
measured in an Ultraspec 2000 photometer (Pharmacia Biotech) and calculated 
according to the following formula: 
 
 
 
Before continuation of work with extracted BAC DNA verification by sequencing was 
suggested by BACPAC Resources to make sure the clone stock they send is pure as their 
libraries have little to well contamination. 
 
3.2.10 Bacterial glycerol stocks 
All steps were done under sterile conditions.  
One ml of an over night culture and 500 µl autoclaved 87% glycerol (Merck) were mixed 
in a cryo tube by vortexing until a homogenous mixture was formed. The glycerol stock 
was stored at -70°C (GFL freezer).  
 
3.2.11 Mutational analysis 
For a complete profile of patient A’s medical history, he was belatedly tested for two 
more typical AML mutations involving the NPM1 and FLT3 genes. From a clinically point 
of view these examinations did not fulfill any purpose since the patient had already 
deceased. 
 
OD260 * 50 * dilution factor 
1000 
= concentration [µg/µl] 
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Mutations in exon 12 of the NPM1 gene result in an alteration of the amino acid 
tryptophan at position 288. This causes a change in the nuclear localization signal with 
consequent cytoplasmic accumulation of the NPM1 phosphoprotein.  
The favorable clinical outcome of NPM1 mutations in patients with normal karyotype will 
be overridden by concomitantly existing FLT3 ITD (internal tandem duplication) 
mutations [31]. 
FLT3 is a tyrosine kinase that shows constitutive activation status in patients with the 
ITD mutation. These patients carry a sequence alteration in the juxtamembrane (JM) 
portion of the protein. As a result, increased proliferation and reduced susceptibility to 
apoptosis in hematopoietic cells arise [39]. FLT3 kinase inhibitors are available as 
therapy and are therefore an option for medical treatment. 
   
The following procedures were performed according to protocols internally developed for 
routine diagnostics. PCR amplifications were run in the Mastercycler ep gradientS 
(Eppendorf).  
  
3.2.11.1 NPM1 mutation detection 
For reverse transcriptase PCR, 2 µl of both available cDNAs were mixed with 15,3 µl 
ddH2O, 2,5 µl 10x PCR Gold Buffer (Applied Biosystems), 2,5 µl 25 mM MgCl2 (Applied 
Biosystems), 0,5 µl 10 mM dNTP mix (Amersham Biosciences), 1 µl 10 pmol/µl NPM1b-
for primer, 1 µl 10 pmol/µl NPM1b-rev primer, and 0,2 µl AmpliTaq GoldTM DNA 
Polymerase (5 U/µl; Applied Biosystems) in a final volume of 25 µl. 
 
Table 3.5 PCR program used for NPM1 mutation detection 
Step Time, Temperature Cycles 
Initial denaturation 5 min at 94°C 1 
Denaturation 
Annealing 
Extension 
30 sec at 94°C 
30 sec at 60°C 
30 sec at 72°C 
40 
Final extension 4 min at 72°C 1 
Pause ∞ at 12°C - 
 
The PCR product was subject to sequencing analysis.  
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3.2.11.2 FLT3-ITD detection  
For PCR amplification 2 µl DNA and 0,4 µl AmpliTaq GoldTM DNA Polymerase (5 U/µl; 
Applied Biosystems) were mixed with 50 µl of a previously prepared mix containing 37,9 
µl ddH2O, 5,3 µl 10x PCR Gold Buffer (Applied Biosystems), 5,3 µl 25 mM MgCl2 (Applied 
Biosystems), 1,1 µl 10 mM dNTP mix (Amersham Biosciences), 0,2 µl 100 pmol/µl ITD F 
primer, and 0,2 µl 100 pmol/µl ITD R primer. 
 
Table 3.6 PCR program used for FLT3-ITD detection 
Step Time, Temperature Cycles 
Initial denaturation 10 min at 95°C 1 
Denaturation 
Annealing 
Extension 
30 sec at 95°C 
30 sec at 54°C 
30 sec at 72°C 
40 
Final extension  min at 72°C 1 
Pause ∞ at 12°C - 
 
For detection of a possibly existent mutation the PCR product was analyzed with the 
help of DHPLC (denaturing high pressure liquid chromatography, Transgenomic®). The 
‘sizing program’ of the associated WAVE® System 4500 was used which does not 
depend on denaturing conditions. Dependent on whether the internal tandem repeats 
are existent the chromatogram will show one peak for wildtype DNA or several peaks for 
mutated DNA. As ITDs increase the length of the target region products of different 
sizes emerge in the PCR amplification and are detected in the DHPLC UV detector 
sequentially according to their size differences, underlying the same principle as in gel 
electrophoresis. Results are converted to digital data by the NavigatorTM Software.  
 
3.2.12 Sequencing analysis 
3.2.12.1 Purification of PCR products 
PCR products subject to sequencing analysis had to be purified first by using the 
ExoSAP-IT® system (USB). 
 
The ExoSAP-IT reagent is used for clean-up of PCR reactions that are used in 
downstream applications such as DNA sequencing. After completion of PCR unconsumed 
dNTPs and primers must be removed from the PCR product mixture as they would 
interfere with the sequencing method. ExoSAP-IT removes these contaminants by the 
use of two hydrolytic enzymes: Exonuclease I and shrimp alkaline phosphatase. 
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Exonuclease I removes any single-stranded DNA including unused primers while shrimp 
alkaline phosphatase converts the remaining dNTPs into inorganic phosphates [40].  
One reaction consisted of 5 µl PCR product and 2 µl ExoSAP-IT and was run in the 
Mastercycler ep gradientS (Eppendorf). 
 
Table 3.7 Program used for ExoSAP-IT purification 
Step Time, Temperature 
Purification reaction 15 min at 37°C 
Inactivation of enzyme 15 min at 80°C 
Pause ∞ at 12°C 
 
If a greater volume of product is needed the reaction can also be carried out with 10 µl 
PCR product and 4 µl ExoSAP-IT reagent.   
 
3.2.12.2 Sequencing reaction 
The DNA template was subsequently processed in the sequencing reaction using the 
BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems).  
 
Cycle sequencing is very similar to PCR since successive rounds of denaturation, 
annealing and extension give rise to amplified extension products. Thereby fluorescent 
fragments are produced by incorporation of labeled ddNTPs. Each different ddNTP 
(ddATP, ddCTP, ddGTP, or ddTTP) carries a different fluorescent dye and so all 
terminated fragments exhibit a dye at their 3´ end [41]. 
 
3.2.12.2.1 Sequencing of ExoSAP purified PCR products 
For each sample two reactions were performed since sequencing was done separately 
for both forward and reverse primers. The same primers were used as in the previous 
PCR amplification. For primer sequences refer to Appendix.  
 
The required volume of the ExoSAP-IT purified PCR product for the sequencing reaction 
depends on the size and the concentration of the amplified fragment. The required 
amount (in ng) is calculated according to a formula that was laboratory internally 
developed: 
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The amount of DNA in the PCR product mixture was estimated with the help of the gel 
picture or with the help of DHPLC (Transgenomic®). Subsequently the concentration 
[ng/µl] could be determined and finally the required volume of PCR product is 
calculated: 
 
 
 
3.2.12.2.2 Direct sequencing of BAC DNA 
For verification of BAC clones extracted DNA was used directly in sequencing reactions 
as no prior PCR and ExoSAP-IT purification were performed.  
 
Applied Biosystems recommend 1 µg of BAC DNA for sequencing analysis. As the 
genomic DNA in the vector is flanked by the SP6 and T7 sites direct sequencing with 
primers complementary to these sites is possible. For vector maps and primer 
sequences refer to Appendix.  
 
For the sequencing reaction 14-x µl ddH2O, x µl DNA, 2 µl BigDye
® Terminator v1.1 
Ready Reaction Mix, 3 µl BigDye® Terminator v1.1 5x Sequencing Buffer and 1 µl 5 
pmol/µl primer (Applied Biosystems) were mixed. The reaction was run in the 
Mastercycler ep gradientS (Eppendorf). 
 
Table 3.8 Program used for all sequencing reactions 
Step Time, Temperature Cycles 
Initial denaturation 30 sec at 96°C 1 
Denaturation 
Annealing 
Extension 
10 sec at 95°C 
5 sec at 50°C 
3 min at 60°C 
25 
Pause ∞ at 12°C - 
 
3.2.12.3 Purification of the sequencing reaction 
The samples had to undergo a final purification step before they could be loaded on the 
genetic analyzer. 
 
required amount (in ng) 
estimated concentration [ng/µl] 
=  required volume (in µl) 
fragment length (in bp) 
100 
=  required amount (in ng) 
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Unincorporated fluorescently labeled ddNTPs and salt would interfere with the 
sequencing analysis and produce poor signal-to-noise ratios. The BigDye® XterminatorTM 
Purification Kit (Applied Biosystems) is used for clean-up which captures the 
contaminants by means of specially developed beads [42].   
 
For purification 45 µl SAM Solution and 10 µl Xterminator Solution were mixed and 
added to 10 µl of the sequencing reaction in a MicroAmp Optical 96-well Reaction Plate 
(Applied Biosystems). The plate is reversibly sealed and vortexed for 30 minutes at 
2000 rpm using the MixMate PCR 96 (Eppendorf).  
Prior to loading the plate on the Genetic Analyzer it needed to be centrifuged for 2 
minutes at 3000 rpm in the Labofuge 400e (Heraeus) so that the beads are collected at 
the bottom of the well and the capillaries of the sequencer would not encounter the 
Xterminator Solution containing the contaminants.  
 
3.2.12.4 ABI 3130 Genetic Analyzer 
After completion of the final purification step the samples were ready for analysis based 
on capillary electrophoresis in the ABI 3130 Genetic Analyzer (Applied Biosystems). 
 
During capillary electrophoresis the products of the sequencing reaction are injected 
into capillaries that are filled with polymer (POP-6TM polymer, Applied Biosystems). An 
electrical field is established which makes the negatively charged DNA fragments move 
through the polymer towards the positive electrode according to their size.  
Before reaching the positive electrode the DNA fragments pass a laser beam which 
causes them to fluoresce. The fluorescence signal is detected by an appropriate detector 
and is converted to digital data by the 3130 Data Collection Software (see figure 3.2) 
[43].  
 
 
Figure 3.2 Working principle of the genetic 
analyzer. The migration of DNA fragments in 
the electrical field toward the laser beam and 
fluorescence detector are illustrated (picture 
from [43]).  
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Prior to starting the genetic analyzer the associated software was used to enter the 
samples’ specifications and to adapt the appropriate settings.  
The MicroAmp Optical 96-well Reaction Plate was placed in the designated tray and the 
specific program could be started.  
 
Data analysis was done with the Applied Biosystems Sequencing Analysis v5.2 Patch2, 
or SeqScape® v2.5 software. The obtained sequence was used for BLAST (Basic Local 
Alignment Search Tool, NCBI) search on the freely accessible website 
http://www.ncbi.nlm.nih.gov/blast/Blast.cgi.  
 
3.2.13 Production of Fluorescently Labeled Probes 
BAC DNA that was previously isolated had to be fluorescently labeled so that it could be 
used as probe in FISH experiments. Labeling was carried out with the Nick Translation 
Kit (Abbott Molecular Inc.). 
This kit incorporates SpectrumGreenTM- and SpectrumOrangeTM-directly labeled dUTPs 
into strands of DNA. 
 
3.2.13.1 Nick translation 
For the labeling reaction nuclease-free water, 1 µg (≤ 17,5µl) extracted BAC DNA, 2,5 
µl 0,2 mM fluorescently labeled dUTP, 5 µl 0,1 mM dTTP, 10 µl 0,1 mM dNTP mix, 5 µl 
10x nick translation buffer and 10 µl nick translation enzyme were mixed in a final 
volume of 50 µl. The reaction was briefly centrifuged, vortexed and run in the PCR 
Express thermal cycler (Hybaid). 
 
Table 3.9 Program used for the labeling reaction 
Step Time, Temperature 
Labeling reaction 16 hours at 15°C 
Reaction stop 10 min at 70°C 
Cooling ∞ at 4°C 
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3.2.13.2 Precipitating the probe 
For precipitation of the probe 5 µl of the nick translation reaction (~ 100 ng labeled 
DNA), 1 µg human COT-1 DNA® (GibcoBRL), 2 µg DNA sodium salt from salmon testes 
(SIGMA®), 4 µl ddH2O, 0,1 volume 3 M NaOAc, ph 5,5, and 2,5 volumes EtOH absolute 
(Merck) were mixed, briefly vortexed and DNA was precipitated at -70°C (GFL) for 20 
minutes. After centrifugation at 13.200 rpm and 4°C for 30 minutes in the Centrifuge 
5415R (Eppendorf) the pellet was dried under vacuum (UNIVAPO 100 H, UniEquip) at 
ambient temperature for 12 minutes. Finally, the pellet was resuspended in 3 µl ddH2O 
and 7 µl Vysis® LSI/WCP® Hybridization Buffer (Abbott Molecular Inc.).  
The probe could now be stored at -20°C or used right away in hybridization assays.  
Before using the probe on the patient material of interest it was first tested on patient 
chromosomes that did not show any structural or numeral abnormalities.  
 
3 M NaOAC, pH 5,5  20,4 g NaOAc . 3 H2O (Merck) 
add 30 ml ddH2O  
adjust pH to 5,2 with glacial acetic acid (Merck) 
ad 50 ml with ddH2O 
 
 
3.3  Cytogenetics 
For cytogenetic studies previously prepared bone marrow cells were used. For each 
patient cells of two differently treated bone marrow cultures were available: 
synchronized and non-synchronized cells.  
For synchronization bone marrow cultures are treated with methotrexate (MTX). MTX is 
a folic acid antagonist which arrests cells during S-phase by reduction of free thymidine 
and thus by inhibiting DNA synthesis [44, 45]. MTX activity is neutralized by addition of 
leucovorin (folinic acid) and thymidine on the next day. Subsequent addition of colcemid 
arrests cells in metaphase by blocking microtubule spindle formation.   
Non-synchronized cells are not treated with MTX but cultivated over night and finally 
arrested in metaphase by colcemid addition. 
Both kinds of cultures are finally hypo-osmotically shocked with KCl and stored in 
Carnoy’s fixative. Cells in fixative can be stored at -20°C for several years.    
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For hybridization assays, cells were dropped onto slides that have previously been 
washed in 70% EtOH and were stored in ddH2O at 4°C. 
 
3.3.1 Whole Chromosome Paints (WCP) 
For whole chromosome paints XCP Human Chromosome Paints (Metasystems, 
Germany) were used. The probes are fluorescently labeled either with FITC or Texas 
Red®. 
 
The slides were removed from the ddH2O container and cells were dropped from about 
30 cm distance when the slides were still wet. For nice spreading of inter- and 
metaphases the slide was breathed upon before incubation on a wet 38°C heating plate 
for a few minutes.  
The back of the slide was dried with paper towel and the hybridization area was marked 
with a diamond pen.  
Now 10 µl of the appropriate probe were applied. If two different probes were used 5 µl 
of each probe were mixed, briefly centrifuged and applied to the slide. To avoid drying-
out of the hybridization area a coverslip was tightly, albeit reversibly, attached to the 
slide with Fixogum Rubber Cement (Marabu). 
The hybridization reaction was carried out in a humidified HybriteTM machine (Vysis) 
using a specific program.  
 
Table 3.10 Hybrite program used for whole chromosome paints  
Step Time, Temperature 
Denaturation 4 min at 75°C  
Hybridization < 24 hours at 37°C 
 
The following day the coverslips were removed and the slides were washed for two 
minutes in wash solution 1 (73°C), for one minute in wash solution 2 (room 
temperature), and rinsed under ddH2O.  
After drying in the darkness 10 µl DAPI II counterstain (125 ng/ml, Abbott Molecular) or 
DAPI Antifade ES (125 ng/ml, Cytocell) and a coverslip were applied.  
The hybridization could now be visualized using an Axioplan2 imaging fluorescence 
microscope (Zeiss) equipped with filter sets for FITC, Texas Red, and 4′,6-Diamidino-2-
phenylindol (DAPI), and images were taken with a Diagnostic Instruments D10ZNC 
camera using the Isis FISH imaging system software (MetaSystems).  
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The slides could be stored at 4°C.  
 
Wash solution 1  0,4x SSC 
    0,3 % IGEPAL® CA-630 (MP Biomedicals) 
    adjust pH to 7,0-7,5 with NaOH 
    store at room temperature up to 6 months 
 
Wash solution 2  2x SSC 
    0,1 % IGEPAL® CA-630 (MP Biomedicals) 
    adjust pH to 7,0-7,5 with NaOH 
    store at room temperature up to 6 months 
 
3.3.2 Hybridization of self-labeled BACs 
3.3.2.1 Hybridization according to manufacturer’s instruction 
Dropping of the cells was done as described for whole chromosome paints. The slides 
were then denatured in 75°C denaturation solution for 5 minutes.  
Denaturation of precipitated BAC probes at 73°C for 5 minutes and dehydration of 
denatured slides for one minute each in 70%, 85% and 100% EtOH were done 
concomitantly.  
The slides were then placed on a 38°C heating plate so that remaining ethanol would 
evaporate.  
Finally, 10 µl probe or alternatively 5 µl of two differently labeled probes were applied to 
the hybridization area on the slide. To avoid drying-out of the hybridization area a 
coverslip was tightly, albeit reversibly, attached to the slide with Fixogum Rubber 
Cement (Marabu). 
For hybridization the slide was placed in a humidified box in a 37°C incubator with 
natural convection, type BD53 (Binder) for 16 hours.  
 
The following day the coverslips were removed, the slides were placed in 73°C wash 
solution 1 (see WCP), agitated for 3 seconds and incubated for 2 minutes. The second 
wash step was carried out in room temperature wash solution 2 (see WCP). Again, the 
slide was agitated for 3 seconds and incubated in the wash solution for 1 minute. 
Application of DAPI and visualization of the fluorochromes was performed as described 
for whole chromosome paints.  
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Denaturation solution  2x SSC 
     70% formamide (Merck) 
     adjust pH to 7,0–8,0 with HCl 
     store at 4°C up to 2 weeks  
 
3.3.2.2 Altered hybridization procedure for more convenience 
In order to possibly adopt the hybridization of self-labeled BACs for routine work a more 
convenient performance of this procedure was established.  
 
Slides were prepared and dropped as described for whole chromosome paints. Easy 
hybridization in the HybriteTM (Vysis) succeeded with the program for locus specific 
probes.  
 
Table 3.11 Program used for hybridization of self-labeled BACs  
Step Time, Temperature 
Denaturation 4 min at 75°C  
Hybridization < 24 hours at 37°C 
 
Washing, application of DAPI and visualization of the fluorochromes were performed as 
described for whole chromosome paints.  
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4  Results 
 
4.1  Patient A: Identification of the ETV6 partner 
gene 
The first approach was the identification of a putative partner gene that is fused to the 
ETV6 locus on chromosome 12 due to the translocation found in patient A.  
 
ETV6 was found to be one part of the fusion gene in a previous project by applying a 
dual color break apart probe for this gene locus. This probe consists of two differently 
labeled halves and is designed to prove a split in the target chromosomal area. For 
demonstrative reasons a picture of the LSI® ETV6 (TEL) Probe Region 12p13 (Abbott 
Molecular Inc.) is shown in figure 4.1.  
 
 
 
The probe was applied to fixed bone marrow cells treated with MTX and visualization 
proved a split between the differentially labeled halves of the probe (figure 4.2).  
Figure 4.1 ETV6 dual color break 
apart probe (picture from [46]). 
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In order to find the partner gene that obviously fused to ETV6 on the 3´end, RACE PCR 
was carried out in the next step.  
 
4.1.1 Amplification of the unknown fusion gene with ETV6 
on the 5´ end 
RACE PCR is a nice method to amplify a DNA fragment of which part of the sequence is 
unknown. It was the method of choice in this matter and primers were designed for the 
already elucidated ETV6 gene.  
 
Two independently synthesized cDNAs, yet from the same RNA template, were available 
so the experiment was performed with both cDNAs in case one of them is of bad quality. 
Next to a positive (template and primers included in the GeneRacerTM kit) and a 
negative control (without template) three PCR amplifications for each cDNA were 
performed. Three distinct primers plus appropriate nested primers were designed. They 
were located in coding exon 2, coding exon 4, and coding exon 5 reaching into coding 
exon 6.  
PCR amplification products analyzed by agarose gel electrophoresis are shown in figure 
4.3. 
 
 
 
 
 
 
 
Figure 4.2 FISH using ETV6 break apart probe. It clearly 
shows a split signal for one allele indicated by two arrows. 
The arrow head marks the fusion signal of the wildtype 
allele. 
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 A        B 
  
 
 
 
 
 
Bands marked with numbers 1 to 7 (figure 4.3 B) were excised, DNA was extracted 
from the gel piece and used for subsequent cloning and sequencing. 
 
 
4.1.2 Searching for clones with the fragment of interest  
After plating of the E.coli cells transformed with RACE PCR products at least 10 single 
colonies were picked from each plate. To analyze their genetic make-up plasmid DNA 
was isolated, amplified via M13-PCR and sequenced. 
 
Sequencing was performed from both sides as ligation of the PCR product could happen 
either way.  
 
4.1.2.1 Sequencing analysis reveals the partner gene of ETV6 
The obtained sequences were fed into the BLAST software. The sequence of the ETV6 
transcript was found in most cases from either side. This makes sense as normal (non-
translocated) ETV6 loci were also present in the original sample. Also, parts of the 
chromosome 12 genomic sequence were obtained as BLAST result with all of them 
containing part of the ETV6 locus. A few results included sequences of the ETV6 
transcript followed by 34 nucleotides of chromosome X that were separated from each 
other by a variable number of nucleotides. In one case part of the TK1 (thymidine 
kinase 1) transcript (chromosome 17) was the result of both directions. This was some 
Figure 4.3 A, B 3´ RACE PCR. The result of the first RACE PCR is shown in A, whereas the nested 
RACE PCR is shown in B where the bands excised for further experiments are marked with numbers 1 
to 7. +C, positive control; -C, negative control. 
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kind of artifact as the translocation between chromosomes 12 and 17 could not be 
proved by subsequent whole chromosome paints. In another case the NTRK3 transcript 
(neurotrophin tyrosine receptor kinase, type 3), also referred to as TrkC, was found on 
the forward sequencing reaction containing the polyA tail of the transcript, whereas the 
reverse reaction identified ETV6 as 5´ part of the transcript. This latter finding was of 
great interest to this project as NTRK3 is located to chromosome 15 which is acrocentric 
as proposed for the unidentified chromosome involved in the translocation with 
chromosome 12.  
As far as the originally identified translocation t(10;12) is concerned, this genetic 
rearrangement was not detected on the level of RNA. A statistical overview of the 
sequencing results is shown below (figure 4.4). 
 
A      B 
Results obtained from forward sequencing
88%
10%
1%
1%
0%
0%
ETV6
chr12
TK1
NTRK3
ETV6 + chrX
not analyzable
 
Results obtained from reverse sequencing
69%
17%
1%
0%
10%
3%
ETV6
chr12
TK1
NTRK3
ETV6 + chrX
not analyzable
 
 
 
 
4.1.3 Verification of the translocation t(12;15) 
Whole Chromosome Paints were performed to verify the translocation involving 
chromosome 15, and thus to augment the probability that the gene NTRK3 on 
chromosome 15 is actually fused to ETV6 on chromosome 12 (see figure 4.5).  
 
Figure 4.4 A, B Statistical view of sequencing results. These two diagrams show the percental distribution 
of sequencing results in forward reaction (A) and reverse reaction (B). 
n = 71 n = 71 
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After proving the existence of this translocation further studies concerning the resulting 
fusion transcript were done.  
 
4.1.4 NTRK3, the ETV6 partner 
NTRK3 is the receptor for a neurotrophin called NT-3. Upon interaction signaling 
cascades are activated that regulate development and maintenance of the vertebrate 
nervous system. NT-3 is widely distributed in neural as well as in non-neural tissues and 
its receptor NTRK3 shows expression in both neural tissues as well as in hematopoietic 
and epithelial cells [47].  
The NTRK3 gene or transcript is organized as follows: exon 1 contains the 5´ UTR and 
encodes the signal peptide. Exons 2 through 9 encode diverse domains, such as two 
cystein clusters, one leucine-rich motif and two Ig-like domains. The transmembrane 
domain is encoded by exons 10 and 11, and the juxtamembrane domain by exons 11 
through 13, while the tyrosine kinase domain is encoded by exons 13 through 18.  
The non-catalytic isoform of NTRK3 exhibits exons 13b and 14b as its final two exons 
which code for an alternative intracellular domain of 83 residues rather than the 
consensus tyrosine kinase domain [48]. This truncated splice variant is also referred to 
as isoform B [49]. The NTRK3 genomic and protein structures are shown below (figure 
4.6). 
 
 
 
 
 
 
 
Figure 4.5 WCP of chromosomes 12 and 15.  
Chromosome 12 is painted red and chromosome 15 
painted green. The arrows indicate the reciprocal 
translocation giving rise to derivate chromosomes 
der(12) and der(15). The arrow head marks the 
additional chromosome 12 translocation. 
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Figure 4.6 A, B Schematic representations of NTRK3. The genomic organization is shown in A and the NTRK3 
peptide isoforms in B. In A the final two coding exons of the truncated isoform are highlighted blue and for 
spatial reasons exons 4-10 are omitted; in B the tyrosine kinase domain is encoded by exons 13-18. EC, 
extracellular domain; TM, transmembrane domain; JM, juxtamembrane domain. (Nomenclature of the exons 
is adopted from [47]). 
 
The truncated NTRK3 proteins are mainly thought to act as dominant negative 
molecules that inhibit signaling of their catalytically active counterparts [50]. Truncated 
NTRK3 was also shown to trigger a signaling pathway leading to membrane ruffling and 
the formation of cellular protrusions [51]. Moreover, mouse models suggest that the 
non-catalytic NTRK3 plays an indispensable role in development [52]. However, its 
exact physiological function remains elusive.  
Alternative splicing can result in two additional isoforms called C and D, which arise 
from in-frame deletion of exon 9 (27 nucleotides) and exon 16 (42 nucleotides), resp. in 
regard to the canonical isoform A depicted in figure 4.6 B [49]. The isoforms C and D 
are not further discussed as they were of no relevance in this diploma thesis. 
 
4.1.5 Characterization of the ETV6-NTRK3 fusion transcript 
After verification of the translocation the fusion transcript was tried to be specified.  
4.1.5.1 RT-PCR proves alternative splicing of fusion transcript 
In order to investigate expression of the chimeric gene on the level of RNA reverse 
transcriptase PCRs were done.   
As the initially found sequence represented the truncated version of the neurotrophin 
receptor kinase the idea that other isoforms could be found as ETV6 partners, too, 
sounded reasonable. This was tested in nested RT-PCR experiments.  
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PCR products are shown in figure 4.7. As positive control patient A cDNA was amplified 
with ABL Iii and ABL IIIi primers specific for the widely distributed c-abl receptor 
tyrosine kinase gene (lane 1, 173 bp).  
In lane 2 the fusion transcript consisting of ETV6 and truncated NTRK3 is clearly 
detectable (142 bp; ETV6exon5 and NTRK3SequF, the latter located in NTRK3 exon 
13b). 
Lanes 3, 4 and 5 show transcripts of ETV6 fused to the catalytically active NTRK3 
isoforms (245 bp, 260 bp and 678 bp, resp.; ETV6exon5 and NTRK3cod.exon14I or 
NTRK3cod.exon14II, or NTRK3cod.exon17 primers, resp., all NTRK3 primers specific for 
the tyrosine kinase domain).  
No signal is obtained for the reciprocal translocation (NTRK3-ETV6) in lanes 8 and 9 
where cDNA was tried to be amplified with NTRK3cod.ex12fw1 and ETV6cod.ex6rev, 
and NTRK3cod.ex12fw and ETV6cod.ex6rev primer sets, respectively. 
Two different negative controls were run in the PCR experiment. First, cDNA from a 
different patient not showing the translocation in question was tried to be amplified by 
use of ETV6exon5 and NTRK3SequF primers (lane 7). Thereby, the fusion was shown to 
be specific for patient A as it was not detected in the other patient. In order to eliminate 
the possibility of a non-functional cDNA template RT-PCR using ABL Iii and ABL IIIi 
primers was run with this other patient’s cDNA (lane 6). 
Second, ddH2O was used in the PCR alongside ETV6exon5 and NTRK3SequF primers 
(lane 10).  
 
4.1.5.2 Identification of coding exons participating in the 
chimeric transcript  
Fusion transcripts were more closely characterized by sequencing of RT-PCR products to 
get an insight into the structure of resulting chimeric transcript and its constituting 
exons.  
Figure 4.7 Nested RT-PCR.  Results 
indicate that ETV6 builds fusion 
transcripts with both the truncated 
and catalytically active NTRK3 
isoforms.  
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Sequencing definitely confirmed the expression of the ETV6-NTRK3 fusion gene in 
patient A. Both the truncated and the catalytically active isoform were verified to be 
fused to ETV6 (see figure 4.8). They were both shown to be in-frame fusion partners of 
ETV6. 
    
 A 
 
 B 
 
 
 
 
 
 
The fusion transcripts are depicted below with ETV6 colored pale orange, and NTRK3 
colored green.   
 
 
Figure 4.8 A, B Sequences of fusion transcripts. Electropherogram shows the fusion transcripts involving ETV6 
and the catalytically active NTRK3 isoform (A) and ETV6 fused to the truncated NTRK3 isoform (B). In either 
case, sequencing was done in both directions with only one being shown. Primer ETV6SequRneuNstd used in A, 
primer ETV6SequRneu used in B. 
Figure 4.9 A, B Proposed structure of 
the entire fusion transcripts. ETV6 
being fused to the catalytically active 
NTRK3 isoform in (A) and to the 
truncated isoform of NTRK3 in (B). 
 
A 
B 
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4.2   Mutational analysis of genes frequently 
involved in AML  
The frequently mutated NPM1 and FLT3 genes in AML were tested for patient A in order 
to have a more complete patient profile. 
 
4.2.1 Analysis of the NPM1 transcript sequence 
Sequencing analysis of the NPM1 exon 12 allows detection of a frequent mutation 
altering the amino acid tryptophan at position 288 resulting in the pathological outcome.  
 
 
 
 
  
Figure 4.10 indicates that sequencing analysis of the patient NPM1 transcript did not 
detect any mutation leading to alteration of the tryptophan residue as marked by the 
cursor position.  
 
4.2.2 Analysis of the FLT3 genomic sequence 
The FLT3 gene is tested for the existence of internal tandem duplications using DHPLC. 
In case of a mutation more than one fragment is amplified during the PCR reaction. 
Thus, further peaks will be obtained in addition to the wild type signal.    
 
Figure 4.10 Electropherogram of NPM1 sequencing. Reference NPM1 transcript (upper sequence) is 
shown in comparison to the patient NPM1 transcript (lower sequence). 
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As illustrated by the above chromatogram (figure 4.11), patient DNA turned out not to 
be mutated since single peaks were obtained in DHPLC analysis. 
 
 
4.3  Implementation of the BAC FISH method 
After completion of a great deal of bureaucracy the import license for E.coli harboring 
BACs issued by the Ministry of Health, Family, and Youth was obtained for our 
laboratory which is valid through June 2009.  
After this absolutely necessary step, appropriate BAC clones were selected for 
downstream experimental procedures. Two different freely accessible data bases on the 
internet were used to search for the BAC clones of interest. On the one hand, the 
University of California, Santa Cruz genome browser 
(http://genome.ucsc.edu/index.html), Assembly March 2006, and on the other hand the 
BAC/PAC collection data base of the University of Bari, Italy 
(http://www.biologia.uniba.it/rmc/) were used for identification of useful BAC clones. 
Selected BACs were then ordered at the BACPAC Resources Center at Children’s 
Hospital Oakland Research Institute (CHORI) in California, USA and subsequently 
labeled by nick translation. These self made DNA probes were then used on non-
pathological patient material to check their specificity and were subsequently hybridized 
on patient material of interest to fulfill their purpose in breakpoint specification.  
Figure 4.11 Chromatogram of FLT3 
analysis. Peak profiles of reference DNA in 
comparison to patient DNA are depicted.  
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4.4  Patient B: Searching for the breakpoint 
According to conventional cytogenetics the patient carried the translocation t(9;21). 
Chromosome bands 9q13 and 21q22 seemed to be involved.  
 
 
 
The translocation t(9;21) was seen in 12 out of 31 metaphases in routine cytogenetics. 
 
To further narrow the area of a possible breakpoint, BACs were ordered according to 
chromosome information available on the University of California, Santa Cruz Genome 
Browser.  
As the band 9q13 can be easily covered by only three different BACs, RP11-2M11, 
RP11-151G22 and RP11-825L14, these were ordered, labeled and used in FISH 
experiments. If the breakpoint actually happened somewhere within this particular band 
a split signal of any two of these BACs will be detectable.  
For illustrative reasons the localization of the BACs relative to the band 9q13, to the 
genes and to each other is shown in the figure below.  
 
 
 
 
 
 
Two rounds of BAC hybridization were carried out. Since the first one using RP11-2M11 
and RP11-151G22 did not result in a split signal (see figure 4.14 A), hybridization with 
RP11-2M11 and RP11-825L14 was performed (see figure 4.14 B), which again delivered 
fusion signals only.  
Figure 4.12 Translocation t(9;21). 
Chromosomes 9 and 21 showing 
structural abnormalities (arrows) due to 
the translocation between them.  
Figure 4.13 Schematic illustration of band 9q13 (500 kb in size). Part of band 9q21.11 and of the 
assigned BAC clones (magenta) relative to the genes (green) are also shown. Not drawn to scale; 
centromeric to telomeric direction as indicated.  
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The BAC RP11-2M11 turned out to show multiple signals on chromosome 9 and an 
additional hybridization signal close to the chromosome 2 centromer (see figure 4.14 A 
and B). Keeping the additional specificity in mind it did not interfere at all with the 
results and validity of the FISH studies.  
 
             A B 
   
 
 
 
 
Despite our expectations no split signal was detectable. Instead, both approaches 
delivered fusion signals on chromosome 9 indicating the breakpoint must occur outside 
the assumed band 9q13.  
 
 
4.5   Patient C: Narrowing of the breakpoint and 
proposal for a candidate gene 
Conventional cytogenetics revealed a translocation involving chromosomes 4 and 13. 
The translocation seemed to be located just underneath the chromosome 13 centromer 
and was therefore designated t(4;13)(q35;q12).  
Figure 4.14 A, B FISH done with 9q13 specific BAC probes. The probes RP11-2M11 (red) and RP11-
151G22 (green) were applied in the FISH experiment shown in A, whereas RP11-2M11 (red) and RP11-
825L14 (green) were used for hybridization in B. In each panel, arrows indicate the fusion signal, arrow 
heads mark the additional specificity of the probe RP11-2M11 for chromosome 2.  
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In routine cytogenetics the translocation was found to be present in virtually 100% of 
the examined meta- and interphases.  
As the breakpoint on chromosome 13 was assumed to be very close to the centromer, 
BAC clones situated in this region were ordered, labeled and used to walk along the 
chromosome until a split signal between two of them appeared. After a few rounds of 
BAC hybridization the breakpoint could be constrained to a region of about 497 kb that 
was flanked by the clones RP11-933M24 and RP11-523H24 (see figure 4.16).  
 
 
 
Within this 497 kb region there is a candidate gene, TPTE62, located. In order to find out 
if this gene might be affected by the translocation, the breakpoint was further 
approximated by two additional BAC clones, namely RP11-134H3 and RP11-1031I2. 
Figure 4.17 gives a schematic overview of the experiment. 
 
 
 
                                            
6 Transmembrane phosphatase with tensin homology 
Figure 4.15 Translocation t(4;13). 
Chromosomes 4 and 13 showing clear 
karyotypic abnormalities (arrows) due to the 
translocation. 
 
Figure 4.17 Schematic representation of the band 13q12.11 (3,8 mb in size). BAC clones narrowing the 
breakpoint to 497 kb are colored magenta, the candidate gene probably involved in the translocation 
(TPTE2) is colored green, and additional BAC clones for further approximation of the breakpoint are colored 
yellow. Centromeric to telomeric direction as indicated.    
Figure 4.16 Hybridization of RP11-933M24 (green) 
and RP11-523H24 (red). The arrow marks the fusion 
signal on non-rearranged chromosome 13. Arrow 
heads indicate the split signal due to the breakpoint 
between the probes. 
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The figure below (figure 4.18) shows the visualization of the RP11-134H3 and RP11-
1031I2 probes which were used in order to further approximate the breakpoint. 
 
         A                B 
 
 
 
 
 
 
As clearly visible in the above figure (figure 4.18), hybridization of these two probes 
definitely showed an additional red signal on the long arm of derivative chromosome 4, 
der(4), which folds back on itself (clearly visible in panel B).  
For clarity the signal pattern is schematically illustrated below (figure 4.19). 
 
 
 
The obtained signal pattern demonstrates that the breakpoint is located within the 
region of RP11-1031I2 (red). This increases the possibility that the translocation 
actually involves the candidate gene TPTE2.  
   
 
Figure 4.18 A,B FISH performed with 13q12.11 specific probes. RP11-134H3 (green) and RP11-1031I2 
(red) were applied. In panel A, arrows mark the fusion signals on normal and pathologic chromosome 13 
as well as the split signal on chromosome 4 (sole red signal). In panel B, chromosomes are shown as 
visualized in the DAPI filter for better visibility of their structural appearance. Arrows mark the 
chromosomes of interest. 
 
Figure 4.19 Illustration of the signal pattern. The probes 
RP11-134H3 (green) and RP11-1031I2 (red) deliver 2 fusion 
signals representing chromosomes 13 and a sole red signal 
representing the derivative chromosome 4. 
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5  Discussion 
The identification of fusion genes and their role in aberrant cellular functions are of very 
great importance in disease and drug research.  
The function of chimeric molecules needs to be elucidated so that therapy can be 
specifically developed. In case of constitutively active kinases, small inhibitors have 
been artificially synthesized that specifically inhibit aberrant enzymatic activity and 
therefore terminate cellular processes like for instance proliferation. In some cases 
inhibitors even show cross-reactive effects, i.e. they act on fusion products they were 
not designed for, e.g. imatinib, originally developed as CML therapy, succeeds in 
treatment of FIP1L1-PDGFRα positive eosinophilia patients.  
The very first step in the process of drug development is the identification of a disease’s 
origin, e.g. the existence of fusion genes. As soon as the exact structure and the role in 
signaling or other processes are known, specific small molecules will be designed that 
act on these pathogenic cellular components. Of course, this whole process is of very 
long duration and is absolutely based on the prior identification of such aberrantly acting 
molecules.             
 
 
5.1  Patient A’s genetic make up 
5.1.1 FLT3 and NMP1 mutational status 
FLT3 and NPM1 were shown not to be mutated, results that were consistent with our 
expectations. Usually, both FLT3 and NPM1 show genetic alteration in up to 33% and 
60%, resp. of cytogenetically normal patients. This patient, though, showed clear 
chromosomal rearrangements and was therefore not expected to be tested positive for 
these molecularly defined mutations. However, we decided to examine their genetic 
status for the sake of a more complete patient profile on possible AML mutations. 
5 Discussion 
- 61 - 
5.1.2 The ETV6 fusion partner 
When sequencing analysis of cloned RACE PCR products was performed one expected to 
detect the ETV6 transcript sequence from the 5´ end, whereas the 3´ polyA end was 
supposed to be part of the fusion partner.  
It was obvious that the ETV6 sequence would also be detected from both ends as the 
translocation was not found in a hundred percent of the patient’s cells and the normal 
ETV6 locus was still present.  
So in most of the sequencing reactions ETV6 was found from either direction. Many other 
results constituted chromosome 12 genomic sequences, yet all of them contained part of 
the ETV6 locus. These results were regarded as worthless in the search for fusion 
partners.  
Furthermore, some ETV6 transcript sequences were found to be followed by an 
inconsistent number of nucleotides that were themselves followed by a short, non-variable 
span of the chromosome X genomic sequence. These cases were not further investigated 
as no physiological role was attributable to this kind of genomic constellation. 
Another sequencing reaction detected the thymidine kinase 1, TK1, transcript from either 
direction. The TK1 gene is located on chromosome 17 and therefore the patient’s material 
was tested for the translocation t(12;17) by WCP assays. As expected, this sequencing 
reaction was some kind of artifact because the translocation was not verified by whole 
chromosome paints. Besides, the fact that TK1 was sequenced from either direction 
indicated that this was some kind of doubtful result. 
One other sequencing result detected ETV6 at the 5´end and the NTRK3 transcript 
sequence at the 3´ polyA containing end. This attracted a great deal of attention as the 
NTRK3 locus is found on chromosome 15 which has an acrocentric shape. This was 
concordant with the unidentified additional chromosome found to be translocated to 
chromosome 12.  
As far as the initially identified t(10;12) is concerned this rearrangement was not detected 
on the level of RNA. Hence, it seems not to be expressed.  
 
5.1.3 ETV6-NTRK3 fusion and its underlying t(12;15) 
Whole chromosome paints confirmed the underlying translocation t(12;15) of the ETV6-
NTRK3 fusion (see figure 4.5). This translocation was not detected by routine chromosome 
banding techniques because it is too cryptic. The regions exchanged between chromosome 
12 and 15 are very similar in size and banding characteristics. Therefore, the translocation 
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is easily overlooked in conventional cytogenetics. Even though the reciprocal translocation 
occurred on the genomic level it was not detectable on the level of RNA by RT-PCR 
suggesting it is not expressed.   
In figure 4.5 another translocation involving chromosome 12 is visualized, most probably 
the initially found translocation t(10;12) which could not be detected on the level of RNA 
by RACE PCR and sequencing. In order to rule out the possibility of a complex 
translocation involving chromosomes 10, 12 and 15, t(10;12;15), whole chromosome 
paints were performed. The visualization of chromosomes 10 and 15 did not show any 
translocation signals (data not shown). Therefore, a complex translocation was excluded.  
 
5.1.4 The ETV6-NTRK3 fusion transcript 
The existence of the translocation t(12;15) was verified on the genomic level by whole 
chromosome paints, and in order to investigate the expression of the fusion genes RT-PCR 
analysis was performed.  
As the NTRK3 transcript that was initially detected by sequencing turned out to represent 
a truncated, non-enzymatic isoform, the existence of further NTRK3 isoforms in the fusion 
transcript suggested itself.  
Even though RT-PCR could not detect the reciprocal NTRK3-ETV6 fusion transcript, it 
succeeded in showing the expression of the originally detected fusion transcript on one 
hand, as well as the expression of the catalytically active NTRK3 isoform as part of the 
fusion on the other hand. In either case primer sets were used that were located in exons 
directly flanking the breakpoint.  
For definite evidence, RT-PCR amplification products were sequenced with appropriate 
primers (see Figure 4.8). Based on these results, the proposed entire fusion transcripts 
contain ETV6 exons 1 through 5 fused to NTRK3 exons 13b and 14b, or NTRK3 exons 13 
through 18, resp. (see Figure 4.9). 
So far, the catalytically active ETV6-NTRK3 fusion proteins have been detected in a 
significant fraction of non-hematopoietic tumors, e.g. secretory breast carcinoma [20], 
congenital fibrosarcoma [53] or mesoblastic nephroma [54]. Their transforming ability is 
based on constitutive activation of the NTRK3 moiety with downstream activation of Ras-
MAP kinase and phosphatidyl inositol-3-kinase (PI3K)-AKT pathways [20]. 
Interestingly, the ETV6-NTRK3 fusion has been reported in only one case of hematological 
malignancy, i.e. an AML (FAB M2) [19]. The reported case in this diploma thesis is an 
AML, too, but M0 according to the FAB classification. Furthermore, there are two clear 
differences between the previously detected hematological ETV6-NTRK3 fusion and the 
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one described here. First, the fusion transcript identified in this study exhibits ETV6 exons 
1 through 5 in contrast to the previously published case which contained only the first four 
ETV6 exons. Therefore, the entire central domain, made up partly of exon 4 and the entire 
exon 5, is still present and might therefore enable further protein-protein interactions. The 
second difference is that ETV6 was only shown to be fused to the catalytically active 
isoform in the earlier report. In our case we demonstrated that alternative splicing of the 
transcribed ETV6-NTRK3 gene takes place and gives rise to the truncated NTRK3 isoform 
which is known to induce signaling that results in membrane ruffling and cellular 
protrusions [51], structural changes that support cell migration.  
Unfortunately, insufficient patient material did not allow the investigation of ETV6-NTRK3 
expression on protein level. The oncogenic activity of both variants remains to be 
revealed. Thereby one must keep in mind that fusion products containing ETV6 have been 
shown to involve diversely regulated aberrant mechanisms. As far as kinase domain 
proteins are concerned, ETV6 influences the fusion partner’s activity via its HLH 
(dimerization) domain [22]. Regarding the ETV6-NTRK3 fusion, data prove that the NTRK3 
kinase domain by itself does not provoke transformation activity. More precisely, it was 
demonstrated that NIH3T3 cells cannot be successfully transformed by ETV6-NTRK3 
chimeric proteins that still possess a perfectly operating NTRK3 kinase domain but lack a 
functional ETV6 HLH domain [55]. In other cases, the ETV6 promotor driving the 
transcription of the fusion gene is thought to confer oncogenic potential [22]. It is possible 
that the two variants of fusion products identified in this case may bear different 
potentials in transforming actions.  
 
5.1.5 Suggestions for continuation 
As mentioned earlier, it was not possible to investigate the fusion on protein level due to 
insufficient patient material. Although cells were available, there was not much material 
left because of the preceding FISH studies. Additionally, these cells were stored in fixative 
making them most probably useless for protein extraction due to denaturing conditions 
and cross-linking procedures during fixation. 
However, one can try to isolate the entire fusion transcript by RT-PCR, clone it into an 
expression vector and have it expressed in vast amounts. In subsequent interaction 
studies, e.g. yeast-2-hybrid systems, binding partners could be searched for to get an 
insight into possible signaling pathways. Also, a myeloid, stably transfected cell line could 
be used to investigate the fusion product’s function. One could examine its influence on 
proliferation, its phosphorylation status or its migration behavior towards chemokines, etc. 
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5.2  Patient B’s untraceable breakpoint at 9q13 
According to conventional cytogenetic data the translocation was assumed to involve 
bands 9q13 and 21q22 and was therefore defined as t(9;21)(q13;q22). The chromosomal 
band 9q13 turned out to be only ~ 500 kb in size and could easily be covered by three 
different BAC clones. When hybridizing these specific probes to the area of interest no 
breakpoint could be located in this region.  
This incidence shows that the correct interpretation of karyograms is very challenging, 
especially when the patient’s metaphases are of poor quality or when the chromosomal 
areas surrounding the band of interest are very similar in size and appearance. Moreover, 
cytogenetics represent a diagnostic approach that differs greatly among patients and 
frequently shows differences in chromosomal structures of individual patients even without 
the existence of pathological chromosomal aberrations.   
 
5.2.1 Suggestion for alternative approaches 
The exact determination of the breakpoint requires additional analyses. One possible 
method is using BAC-FISH to walk along the affected chromosome arm and get an insight 
into the relative location of the breakpoint. The greater the target area is in size the more 
rounds of hybridization assays are required and thus, a considerable amount of patient 
material will be needed. An alternative to this cost-effective but material consuming 
method would be the usage of multicolor chromosome banding kits (MetaSystems, 
Germany). These differently labeled, region-specific paints represent a very good method 
to locate chromosomal rearrangements. Even though this latter approach is less time and 
material consuming, multicolor chromosome banding paints with sufficient resolution are 
not available for every arbitrary chromosomal region.  
 
 
5.3  Detection of a candidate gene for patient C 
The translocation t(4;13) involved the band 13q12.11 which is almost 4 mb in size. With 
the help of BAC probes this region was successfully narrowed down to a smaller area of 
only 497 kb. A candidate gene within this chromosomal band could also be identified, 
TPTE2.  
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5.3.1 TPTE2 – a tumor suppressor phosphatase? 
TPTE2, or alternatively called TPIP7 [56], is a phosphatase of the PTEN8 tumor suppressor 
family [57]. Several splice variants exist, two of which seem to be functionally different. 
TPIPα is localized to the endoplasmic reticulum membrane and possesses phosphatase 
activity to metabolize phosphatidylinositol 3,4,5-trisphosphate. By contrast, TPIPβ lacks 
phosphatase acitivity and is found in the cytoplasm [58]. TPIPα might represent a tumor 
suppressor and functional homologue of PTEN which inhibits cell cycle progression, cell 
survival and motility by antagonizing PI3-kinase activity via dephosphorylation of 
phosphatidylinositol 3,4,5-trisphosphate [59].  
 
5.3.2 TPIP, a proposed candidate but not definitely 
translocated 
When TPIP was identified as candidate gene no definite evidence for actual translocation 
could be provided, though. The region between the BAC probes RP11-933M24 and RP11-
523H24 was demonstrated to include the breakpoint (see figure 4.16). Two more BACs 
were then applied as probes, one of which, RP11-1031I2 (red), spanned the whole TPTE2 
gene reaching into the non-coding area telomeric to TPTE2. An additional BAC probe, 
RP11-134H3 (green), was hybridized which was located centromeric to the candidate gene 
and reached into it (see figure 4.17). The idea was that if the breakpoint occurs very close 
to the centromeric end of the gene, a hybridization signal probably won’t arise in case the 
complementary regions between the gene and RP11-1031I2 were too short. That is why 
the green RP11-134H3 was hybridized, too. 
According to the signal pattern obtained (2 fusion signals, 1 red signal), the breakpoint is 
definitely located downstream of the RP11-134H3’s telomeric end and within RP11-
1031I2. This is because the 2 fusion signals represent the normal chromosome 13 as well 
as the shortened version of chromosome 13 emerging from the translocation. The sole red 
signal is therefore located to the derivative chromosome 4 representing the second half of 
the broken RP11-1031I2.  
The only question that still remains now is if this probe’s signal is broken within the coding 
region of the TPIP gene or if the breakpoint is located even closer to the telomere and 
thus within non-coding areas of chromosome 13. The length of the non-coding region 
complementary to the RP11-1031I2 probe is 67 kb in size. It is possible that the 
                                            
7 TPTE and PTEN homologous inositol lipid phosphatase 
8 Phosphatase and tensin homologue deleted on chromosome 10 
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breakpoint occurs in this non-coding area so that the probe would still be able to 
hybridize. In order to continue on this issue, definite proof needs to be provided whether 
or not TPTE2 is affected by the translocation. 
 
5.3.3 Suggestions for continuation 
In order to definitely identify or exclude TPTE2 as translocated gene, further BAC 
hybridization assays could be performed. In case of confirmation, its chromosome 4 fusion 
partner needs to be detected. This can be done by RACE PCR again which turned out to be 
a nice and reliable method in this matter as is shown for patient A. Designing an 
appropriate RACE PCR can be challenging, though, in this case as TPTE2 seems to exist in 
multiply expressed isoforms. Thus, the RACE PCR probably results in many different bands 
representing various isoforms in the fusion transcript.  
 
 
5.4  BACs – suitable tools in routine? 
The usage of BACs as DNA probes was successfully established and they were effectively 
applied in fluorescence in-situ hybridizations. Moreover, they represent a more cost-
efficient method compared to commercially available, ready-to-use DNA probes. 
Despite the fact that it takes about 14 working days from the day of BAC order to the day 
of visualization in the fluorescence microscope, BAC FISH represents a very nice and 
suitable method for routine diagnostics.  
Routine is restricted to tests that are run frequently. Thus, BACs needed for this purpose 
have to be ordered once and made ready for labeling. These fluorescently labeled probes 
are made fast and can be re-made from the glycerol stocks of specific BAC clones virtually 
an unlimited number of times. 
The application of BAC FISH in routine diagnostic is of considerably great importance since 
purchasable probes are not available for all of the diagnostically interesting chromosomal 
breakpoints, including rearrangements considered in the WHO classifications of tumors.  
Therefore, BAC FISH represents an important and efficient as well as considerably low-
cost method for diagnostic purposes. 
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A.  Appendix 
 
A.1  Primers 
Primers marked with (1) one asterisk (*) were ordered at Metabion international AG, (2) 
two asterisks (**) were ordered at TIB Molbiol, (3) three asterisks (***) were ordered at 
genXpress, and all other primers were ordered at Applied Biosystems. Primers are listed in 
alphabetical order.  
 
 
Table A.1.1 Primers (5´ 3´) used for RACE PCR 
 
Name Sequence 
ETV6A CAT ATA CAC CTC CAG AGA GCC CAG TGC 
ETV6Anested CTT CAT GTT CCA GTG CCT CGA GCG C 
ETV6B CTG AAG CAG AGG AAA CCT CGG ATT C 
ETV6Bnested CAC CCT GGA AAC TCT ATA CAC ACA CAG C 
ETV6C CAT GCC CAT TGG GAG AAT AGC AGA CTG 
ETV6Cnested CTG ACA GCC GGT ACG AAA ACT TCA TCC 
 
Table A.1.2 Primers (5´ 3´) used for PCR experiments 
 
Name Sequence 
ABL IIi** GCC TCA GGG TCT GAG TGA AGC CGC TCG TTG 
ABL IIIi** TGT GAT TAT AGC CTA AGA CCC GGA GCT TTT C 
ABL IIIo** CCA TTT TTG GTT TGG GCT TCA CAC CAT TCC 
ABL IIo*** CAG CGG CCA GTA GCA TCT GAC TTT G 
ETV6cod.ex6rev* GAT TCT TTG TCC TCC CAT CG 
ETV6cod.ex8rev* GCC ACT CAT GAT TTC ATC TG 
ETV6exon5* ATG CCC ATT GGG AGA ATA GC 
ETV6SequRneu CCC ATC AAC CTC TCT CAT CG 
ETV6SequRneuNstd* CTC TCT CAT CGG GAA GAC C 
ITD F* GCA ATT TAG GTA TGA AAG CCA GC 
ITD R* CTT TCA GCA TTT TGA CGG CAA CC 
M13F TGT AAA ACG ACG GCC AGT 
M13R CAG GAA ACA GCT ATG ACC 
NPM1b-for GGT TCT CTT CCC AAA GTG G 
NPM1b-rev GGC ATT TTG GAC AAC ACA TTC 
NTRK3cod.ex11fw* CCT GTT GGT GGT TCT CTT CG 
NTRK3cod.ex12fw* GGA CAC AAC TGC CAC AAG C 
NTRK3cod.ex12fw1* CAT CCC TGT CAT TGA GAA CC 
NTRK3cod.exon14I* AAC TTG ACA ATG TGC TCA TGC 
NTRK3cod.exon14II* CCG CAC ACT CCA TAG AAC 
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NTRK3cod.exon17* GAA CTT CCG GTA CAT GAT GC 
NTRK3PTKisoA,C,D CCT CCG TGT TTG AGA GTT G 
NTRK3SequF AAG ACA CTT CCC CAC TCT GG 
 
Table A.1.3 Primers (5´ 3´) used for sequencing  
 
Name Sequence 
ETV6SequRneu CCC ATC AAC CTC TCT CAT CG 
ETV6SequRneuNstd CTC TCT CAT CGG GAA GAC C 
M13F TGT AAA ACG ACG GCC AGT 
M13R CAG GAA ACA GCT ATG ACC 
NPM1b-F GGT TCT CTT CCC AAA GTG G 
NPM1b-R GGC ATT TTG GAC AAC ACA TTC 
NTRK3cod.exon14I AAC TTG ACA ATG TGC TCA TGC 
NTRK3cod.exon14II CCG CAC ACT CCA TAG AAC 
NTRK3SequF AAG ACA CTT CCC CAC TCT GG 
SP6 ATT TAG GTG ACA CTA TAG 
T7 TAA TAC GAC TCA CTA TAG GG 
 
 
A.2 DNA markers 
      
      A        B      C 
 
 
 
 
 
 
Figure A.2.1 A, B, C DNA markers 
used for agarose gel electrophoresis. 
O’RangeRulerTM 200 bp DNA Ladder in 
A, MassRulerTM DNA Ladder, Low 
Range in B, pUC19 Hpa II DNA Marker 
in C (pictures adopted and slightly 
modified from [60]). 
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A.3  Vectors 
The vectors below were either used for cloning procedures within the RACE experiment or 
they harbored the genomic fragment of interest which were ordered as BAC clones from 
the BACPAC Resources Center, Oakland, California.  
 
 
 
A          B 
  
 
 
 
 
 
Figure A.3.1 pCR®4-TOPO® vector 
used for cloning of RACE PCR 
products (figure adopted from 
[38]). 
Figure A.3.2 A, B BAC clones that were ordered as E.coli LB stabs at BACPAC Resources are 
constructed either in pBACe3.6 or pTARBAC2 vectors (pictures from [61]). 
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A.4  BAC clones 
Table A.4.1 BAC clones used in FISH experiments.  
Name Chromosome Chromosomal localization Specificity 
RP11-64I8 13q12.3 30 406 381 – 30 571 172 ensured 
RP11-910O20 13q12.3 29 971 980 – 30 126 905 ensured 
RP11-764B5 13q12.3 27 809 291 – 27 962 431 ensured 
RP11-367D4 13q12.13 25 764 973 – 25 929 701 ensured 
RP11-309I15* 13q12.12 23 481 640 – 23 597 770 ensured 
RP11-149B7* 13q12.11 20 826 877 – 20 994 706 ensured 
RP11-523H24 13q12.11 19 098 345 – 19 306 540 ensured 
RP11-1031I2 13q12.11 18 880 857 – 19 076 436 ensured 
RP11-134H3 1312.11 18 758 361 – 18 901 819 ensured 
RP11-933M24 13q12.11 18 413 567 – 18 600 943 ensured 
RP11-825L14 9q13-9q21.11 70 367 430 – 70 586 283 ensured 
RP11-151G22 9q13 70 224 828 – 70 389 343 ensured 
RP11-2M11 9q13 70 027 036 – 70 186 337 
ensured; plus several signals on 
chr9 and an additional on chr2 
All BAC clones were found on the UCSC Genome Browser (http://genome.ucsc.edu/index.html) except  
those marked with an asterisk (*) which were chosen with the help of the BAC/PAC collection database  
of the University of Bari, Italy (http://www.biologia.uniba.it/rmc/). 
 
 
A.5  mRNA sequence information  
 
A.5.1  ETV6 transcript 
GenBank Accession number NM_001987, Version NM_001987.4.  
 
A.5.2  NTRK3 transcript 
A.5.2.1  NTRK3 transcript variant 1 
GenBank Accession number NM_001012338, version NM_001012338.1.  
This isoform can be referred to as the full-length isoform (isoform A) and all other 
isoforms represent splice variants of it. One of the alternatively spliced transcripts 
(isoform B) is referred to in A.5.2.2.  
 
A.5.2.2  NTRK3 transcript variant 3 
GenBank Accession number NM_001007156, version NM_001007156.1.  
Due to data base discrepancies this isoform appears as transcript variant 3 in the NCBI 
GenBank but is called isoform B in this work referring to the uniprot.org data base.   
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B. Abbreviations 
 
AML acute myeloid leukemia 
BAC bacterial artificial chromosome 
bp base pairs 
CAM chloramphenicol 
cDNA complementary deoxyribonucleic acid 
(d)dATP (di)deoxy adenosin triphosphate 
(d)dCTP (di)deoxy cytidin triphosphate 
(d)dGTP (di)deoxy guanosin triphosphate 
(d)dNTP (di)deoxy nucleotide triphosphate 
(d)dTTP (di)deoxy thymidin triphosphate 
DEPC diethyl pyrocarbonat 
DNA deoxyribonucleic acid 
dT deoxy thymidine 
DTT dithiothreitol 
dUTP deoxy uridin triphosphate 
E.coli Escherichia coli 
FISH fluorescence in-situ hybridization 
FITC fluorescein isothiocyanate 
Kan kanamycin 
kb kilo base pairs 
LB Luria Bertani 
mb mega base pairs 
M-MLV Moloney murine leucemia virus 
MTX methotrexate 
OD260 optical density at a wavelength of 260 nm 
PCR polymerase chain reaction 
RACE rapid amplification of cDNA ends 
RNA ribonucleic acid 
rpm rotations per minute 
RT reverse transcriptase 
U units 
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Abstract published in Onkologie, International Journal for Cancer Research and 
Treatment, Vol. 31, Supplement 4, 2008. Available online at www.karger.com/onk and 
also as ISBN 978-3-8055-9021-1. 
 
 
A Translocation between Chromosome 12 and Chromosome 15 leads to a novel ETV6-
NTRK3 Fusion Transcript in Acute Myeloid Leukemia 
 
Kralik J.1, Tschurtschenthaler G.2,3, Kranewitter W.1, Lang F.3, Wiesinger K.4, Gruber C.5, Irnstofer P.1, Petzer 
A.3, Michlmayr G. 3, Webersinke G. 1 
1Laboratory for Molecular Biology and Tumorcytogenetics, Department of Internal Medicine, 2Laboratory for 
Hematology, Department of Internal Medicine, 3Department of Internal Medicine, 4Institute of Laboratory 
Medicine BB&BS,  5Institute for Pathology, Hospital of the Sisters of Mercy, Linz, Austria 
 
Introduction: Chromosomal translocations involving two or more chromosomes are found in many 
hematological malignancies. As a consequence fusion genes arise which may provide the cell with proliferation 
advantages. In this study the ETV6 (ETS variant gene 6) gene is involved in a translocation event in a 54-year-old 
AML patient and the aim was to identify the partner of the resulting fusion gene. Methods: After morphological 
diagnosis of AML cells of peripheral blood and bone marrow were analyzed for surface and cytoplasmatic marker 
expression by flow cytometry (Becton Dickinson, CA). Conventional karyotyping (GTG-banding) was performed 
using bone marrow cultures. In addition to monosomy 7 a translocation involving the ETV6 gene was proven by 
ETV6 break apart FISH. A 3´RACE-PCR was performed to characterize the unknown 3´end of the fusion 
product. The PCR products were subsequently cloned and sequenced. A reverse transcriptase PCR was used to 
verify the rearrangement. Results: In a 54-year-old male patient with recurrent infections and anemia AML with 
minimal differentiation (FAB M0) and multilineage dysplasia was diagnosed. Immunological phenotyping of the 
blasts confirmed a CD34 pos., CD13 pos., CD33 pos., CD56 pos., CD7 pos., CD2 pos., MPO negative population. 
Whole chromosome paints confirmed a t(12;15)(p13;q25). An ETV6 break apart FISH demonstrated an 
involvement of this gene. A 3´RACE-PCR and subsequent sequencing analysis identified NTRK3 (neurotrophic 
tyrosine receptor kinase 3) as in-frame fusion partner of the ETV6 gene. NTRK3 is located on chromosome 
15q25.3 and its transcripts encode either catalytically active proteins or truncated isoforms that lack the 
intracellular kinase domain. The ETV6-NTRK3 transcript fuses ETV6 exons 1 through 5 with exons 13b and 14b 
of a truncated NTRK3 isoform and encodes a protein that contains the amino-terminal HLH domain of the ETV6 
protein and C-terminal amino acids 529-612 of the NTRK3 protein.  
Treatment of the patient with Alexan (100mg/m2 d 1-7) and Idarubicin (12 mg/m2 d 1-3) resulted in a partial 
remission. After HAM and FLAG-Ida and Anti-CD34 recombined monoclonal antibody (Myelotarg®) the patient 
died due to progression of the disease. Conclusions: We identified a novel ETV6-NTRK3 gene fusion in a patient 
with minimal differentiated AML. Interestingly, this chromosomal rearrangement is documented in a significant 
fraction of patients with secretory breast cancer and congenital fibrosarcoma. 
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